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Priority Setting, Cost-Effectiveness, and
the Affordable Care Act
Govind Persad
The Affordable Care Act (ACA) may be the most important health law statute in
American history, yet much of the most prominent legal scholarship examining it has
focused on the merits of the court challenges it has faced rather than delving into the
details of its priority-setting provisions. In addition to providing an overview of the
ACA 's provisions concerning priority setting and their developing interpretations, this
Article attempts to defend three substantive propositions.
First, I argue that the ACA is neither uniformly hostile nor uniformly friendly to
efforts to set priorities in ways that promote cost and quality.
Second, I argue that the ACA does not take a single, unified approach to priority
setting; rather, its guidance varies depending on the aspect of the healthcare system at
issue (Patient Centered Outcomes Research Institute, Medicare, essential health
benefits) and the factors being excluded from priority setting (age, disability, life
expectancy).
Third, I argue that cost-effectiveness can be achieved within the ACA's
constraints, but that doing so will require adopting new approaches to cost-
effectiveness and priority setting. By limiting the use of standard cost-effectiveness
analysis, the ACA makes the need for workable rivals to cost-effectiveness analysis a
pressing practical concern rather than a mere theoretical worry.
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I. INTRODUCTION
In drafting the Affordable Care Act (ACA), policymakers faced delicate and
politically explosive tradeoffs between expanding access to medical care and
controlling the ever-increasing cost of that care. This Article conducts a detailed
examination of several provisions of the ACA, introduced as the ACA traced its
tortuous path from introduction to enactment, that limit the healthcare system's use of
cost-effectiveness analysis, a technique that quantifies the cost and expected benefit of
medical interventions and enables actors within the system to set priorities.1
Part I of this Article introduces three representative patients and presents the
problem of priority setting in healthcare. Priority setting takes place at a variety of
different levels within the healthcare system, ranging from basic science research to
federal policy to individual physician-patient interactions. And priority-setting
decisions can potentially save-or cost-more lives than even some of the most
discussed innovations and mistakes within medical care.
Part II then turns to the text of the ACA, analyzing a variety of provisions that
regulate the priority-setting options of different actors in the healthcare system. Part
II.A discusses provisions that prevent the Patient Centered Outcomes Research
Institute (PCORI) from employing priority-setting approaches that disadvantage
people with disabilities. Part II.B discusses similar provisions that restrict the
considerations Medicare can employ when making reimbursement or coverage
decisions. Part II.C discusses restrictions on priority setting for essential health
benefits. Part II.D discusses priority setting for health plans offered through Health
Insurance Exchanges. In discussing these provisions, I draw on parallels with both tort
and antidiscrimination law. My ultimate concern is that these provisions generate an
inconsistent set of priority-setting rules that threaten to hamstring cost control efforts
without substantially improving population health.
Part III offers solutions to the challenges that the provisions discussed in Part II
pose. Part III.A proposes an approach to cost-effectiveness analysis that avoids
disadvantaging people with preexisting disabilities in a manner prohibited by the
ACA. Part III.B discusses when considering age in priority setting is and is not
appropriate under the ACA. Part III.C discusses how cost-effectiveness analysis can
equitably respond to the different healthcare needs of different groups within a
'See WORLD HEALTH ORG., WHO GUIDE TO COST-EFFECTIVENESS ANALYSIS 3-5 (T. Tan-Tores
Edejer et al. eds., 2003) (discussing the basics of cost-effectiveness analysis).
2 See id. at 84-85 (illustrating how the use of cost-effectiveness analysis can lead to a gain in healthy
life expectancy).
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population.
In addition to providing an overview of the ACA's provisions concerning priority
setting and their developing interpretation, this Article attempts to defend three
substantive propositions. First, I argue that the ACA is neither uniformly hostile nor
uniformly friendly to priority-setting efforts that promote cost and quality. Second, I
argue that the ACA does not take a single, unified approach to priority setting; rather,
its guidance varies depending on the aspect of the healthcare system at issue (PCORI,
Medicare, essential health benefits) and the factor being excluded from priority setting
(age, disability, life expectancy). Third, I argue that cost-effectiveness can be achieved
within the ACA's constraints, but only by adopting new approaches to cost-
effectiveness and priority setting. While several authors have criticized the prevailing
cost-effectiveness approaches used in medical contexts as insufficiently sensitive to
important normative considerations, 3 these criticisms have had little force because the
prevailing approaches are widely adopted and easy to operationalize. By limiting the
use of standard cost-effectiveness analysis, the ACA makes the need for workable
rivals to cost-effectiveness analysis a pressing practical concern rather than a mere
theoretical worry.
A few commentators on the ACA have noted the provisions I discuss, 4 as have
some commentators on comparative effectiveness and cost-effectiveness in medical
care more generally. 5 Some of these authors regard the ACA's priority-setting
provisions as largely or completely precluding the use of cost-effectiveness analysis, 6
while others regard these provisions as ineffectual window dressing that fails to set
meaningful limits on the choices of healthcare decision makers. 7 Even though priority-
setting provisions affect a wide swath of actors in the healthcare system-ranging
from private insurers to administrators to potential litigants challenging insurance
decisions-legal scholarship has yet to discuss them at length. In particular, no article
has yet discussed the United States Department of Health and Human Services' Final
Rule that codifies the ACA's provisions, nor has any discussed the question of how far
the ACA extends the antidiscrimination paradigm into the fields of health insurance
and medical care. In this Article, I both provide a systematic analysis of these
provisions and begin a broader conversation.
3 See, e.g., Christopher J.L. Murray et al., Development of WHO Guidelines on Generalised Cost-
Effectiveness Analysis, 9 HEALTH ECON. 235 (2000), available at http://www.who.int/choice/publications/
p 2000 guidelines generalisedcea.pdf.
4 See Allison K. Hoffman, Three Models of Health Insurance: The Conceptual Pluralism of the Patient
Protection and Affordable Care Act, 159 U. PA. L. REV. 1873, 1905-06 (2011) (arguing that restrictions on
priority setting for essential health benefits reflect antidiscrimination commitments); James Dabney Miller,
The Patient-Centered Outcomes Research Institute, 4 J. HEALTH & LIFE SCI. L. 4, 19 (2010) (discussing
restrictions on priority setting within PCORI); Richard S. Saver, Health Care Reform's Wild Card: The
Uncertain Effectiveness of Comparative Effectiveness Research, 159 U. PA. L. REV. 2147, 2166-67 (2011)
(discussing restrictions in the use of comparative-effectiveness research within Medicare).
5 See Sharona Hoffman & Andy Podgurski, Improving Health Care Outcomes Through Personalized
Comparisons of Treatment Effectiveness Based on Electronic Health Records, 39 J.L. MED. & ETHICS 425,
428 (2011) (summarizing critics' views of cost-effectiveness research); Nadia N. Sawicki, Patient
Protection and Decision-Aid Quality: Regulatory and Tort Law Approaches, 54 ARIZ. L. REV. 621, 641-42
(2012) (discussing cost-effectiveness research and the balance of patient values regarding quality and length
of life); Emily S. Stopa, Comment, Harnessing Comparative Effectiveness Research to Bend the Cost Curve
and Achieve Successful Health Reform: An Assessment of Constitutional Barriers to Limiting Health Care
Treatment Options, 13 U. PA. J. CONST. L. 815, 832-46 (2011) (discussing potential constitutional
challenges to the use of cost-effectiveness analysis in priority setting).
6 See, e.g., Saver, supra note 4, at 2168.
'E.g., Stephen L. Mikochik, Rationing Human Life: Health Care Reform and People with Disabilities,
26 ISSuES L. & MED. 199, 204-05 (2011).
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More importantly, this Article offers novel positive solutions to the problems that
these provisions pose. These solutions have applicability not only for the growing field
of legal scholarship surrounding the ACA, but also for empirical and conceptual work
on cost-effectiveness more generally. This Article explores alternatives to traditional
cost-effectiveness analysis, which could help healthcare priority setting accord better
with public preferences as well as with antidiscrimination goals.
II. PRIORITY SETTING IN MEDICAL CARE
Imagine three cancer patients:
* Alice, 70, has breast cancer. Untreated, her life expectancy is
estimated at five years. Treatment could cure her cancer, but,
because of her advanced age, would add only five years to her
untreated life expectancy.
* Bill, 60, has metastatic prostate cancer. Untreated, he can expect
to live for three months; treatment could add five years to that
estimate.
* Caroline, 30, has osteosarcoma of the leg. Untreated, she is
expected to live for five more years; treatment would require
amputating her leg, but would leave her completely cancer free.
She is also hearing impaired.
Priority setting at different sites and different levels within the healthcare system
shapes Alice, Bill, and Caroline's options in myriad ways. Choices about priorities at
the "micro level"Ithat is, choices about which specific individuals should receive
which treatments -will affect these patients' options in the most obvious way.
Principles and procedures for the micro-level allocation of resources have been most
vigorously discussed in contexts where resources are absolutely scarce: when
physicians on the battlefield are asked to engage in triage, 9 when a pandemic leads to
vaccine shortages, or when choices must be made about which patient will receive an
organ transplant.11 However, micro-level rationing also takes place in more mundane
' For this useful terminology, I draw on, Note, Scarce Medical Resources, 69 COLUM. L. REV. 620,
670-71 (1969).
9 See, e.g., James F. Childress, Triage in Neonatal Intensive Care: The Limitations of a Vletaphor, 69
VA. L. REV. 547, 548 (1983); see also Thomas B. Leary, Comm'r, Fed. Trade Comm'n, Special Challenges
for Antitrust in Health Care, Address at a Forum on Antitrust and Health Care (May 15, 2003), in 18
ANTITRUST 23, 25 (2004) ("Triage is still something that is hard for people to contemplate outside a
battlefield because of the innate reluctance to acknowledge any limits on the 'value of a human life,' but a
market system that tends to give priority to cases where the treatments are most likely to succeed may be
better than the alternatives. In fact, for certain special medical procedures, like organ transplants, this seems
to be the way treatment is rationed today.").
'o Examples of statutes addressing priority setting in a pandemic include, 42 U.S.C § 247d-1(b) (2012)
(discussing the need for "estimates of high priority populations, as determined by the Secretary, in State,
local, and tribal jurisdictions in order to inform Federal, State, local, and tribal decision makers during
vaccine shortages and supply disruptions") and ARK. CODE ANN. § 20-10-1304(d)(2) (2014) (noting that
"during the outbreak of a pandemic disease, the department may enforce vaccine priorities necessary to limit
the loss of life among citizens and to contain the spread of the disease"). For scholarly commentary, see Carl
H. Coleman, Allocating Vaccines and Antiviral Medications During an Influenza Pandemic, 39 SETON
HALL L. REV. 1111, 1111-12 (2009) and Necia B. Hobbes, Note, Out of the Frying Pan into the Fire:
Heightened Discrimination & Reduced Legal Safeguards When Pandemic Strikes, 72 U. PITT. L. REv. 779,
810 (2011).
" See 42 U.S.C. § 274(2)(B) (2012) (authorizing the Organ Procurement and Transplantation Network
to "establish membership criteria and medical criteria for allocating organs and provide to members of the
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contexts: physicians' decisions about which tests to order, how much time to spend
with a patient, or which treatments to prescribe all reflect judgments about priorities.12
Priority setting at other levels of the healthcare system affects patients' options as
well. A 1969 student note in the Columbia Law Review makes the point as well as
anything since:
The decisions of particular hospitals or doctors in their selection of
specific patients for an available treatment-decisions which might be
characterized as "micro-allocation"-form only one aspect of medical
resource allocation. Equally significant in affecting the ultimate
availability and distribution of these resources are the determinations and
underlying policies of a wide variety of persons and institutions-public
and private alike-who are quite far removed from the immediate
context of patient treatment. Congressional appropriations of research
funds, the activities of national health organizations, state underwritings
of specialized treatment costs, budgetary allocations within federal
agencies maintaining public hospital facilities, and the adjustment of
coverage by private health insurance companies are some of the
activities which are part of the second phase of medical facilities
distribution: the process of "macro-allocation."13
Much of this priority setting, rather than establishing hard limits on whether a
given patient receives a given treatment, operates by affecting the cost and supply of
different treatments. Medical insurers may reimburse treatments for different
conditions at different rates,14 while formularies and practice guidelines may
recommend some treatments over others and deny reimbursement for unproven
treatments. 15 Value-based insurance designs, which reduce or eliminate copayments
public an opportunity to comment with respect to such criteria"); Neal R. Barshes et al., Justice,
Administrative Law, and the Transplant Clinician: The Ethical and Legislative Basis of a National Policy on
Donor Liver Allocation, 23 J. CONTEMP. HEALTH L. & POL'Y 200, 227 (2007). For a detailed discussion of
the principles and systems employed in micro-level rationing of scarce resources, see Govind Persad et al.,
Principlesfor Allocation of Scarce Medical Interventions, 373 LANCET 423 (2009).
12 See Mark A. Hall, Rationing Health Care at the Bedside, 69 N.Y.U. L. REV. 693, 711-14 (1994).
'3 Scarce Medical Resources, supra note 8, at 670-7 1.
14 See TEx. GOV'T CODE ANN. § 533.005(a)(2) (West Supp. 2014) ("A contract between a managed
care organization and the commission for the organization to provide health care services to recipients must
contain ... capitation rates that ensure the cost-effective provision of quality health care."); Carrao v. Health
Care Serv. Corp., 454 N.E.2d 781, 786 (Ill. App. Ct. 1983) (noting that Illinois state law requires a
healthcare service corporation to "make a vigorous, good-faith effort to contain rates of reimbursement to
hospitals and other participating health care providers as well as to promote cost-effective alternative forms
of health care" (emphasis omitted)).
" See FLA. STAT. ANN. § 409.91195(8) (West 2013) ("The committee shall develop its preferred drug
list recommendations by considering the clinical efficacy, safety, and cost-effectiveness of a product.");
KAN. STAT. ANN. § 39-7121a(b) (Supp. 2013) ("[T]he department of health and environment shall evaluate
drugs and drug classes to determine whether inclusion of such drugs or drug classes in a starter dose
program would be clinically efficacious and cost effective."); MINN. STAT. ANN. § 256B.0625(13)(d) (West
2007) (stating that decision makers considering whether to include treatments in the state's medical
assistance formulary should evaluate whether the treatments are "necessary, appropriate, and cost-effective
for the treatment of certain specified chronic diseases, conditions, or disorders"); N.M. STAT. ANN. § 27-2C-
3(A) (West 2011) ("The department shall develop or implement a formulary or preferred drug list, taking
into consideration the clinical efficacy, safety and cost-effectiveness of a product."); 32 C.F.R. §
199.21(c)(1) (2014) (establishing a committee to ensure that, within the TRICARE program, "the selection
of pharmaceutical agents for the uniform formulary is based on broadly representative professional expertise
concerning relative clinical and cost effectiveness of pharmaceutical agents"); see also Russell Korobkin,
Comparative Effectiveness Research as Choice Architecture: The Behavioral Law and Economics Solution
to the Health Care Cost Crisis, 112 MICH. L. REV. 523, 549 (2014) ("Many insurance plans come with
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for certain drugs or even pay patients to choose those drugs, may also provide patients
with financial incentives to choose specific treatments.16 Even more general decisions
in the healthcare system-such as which specialties prospective physicians are
encouraged to pursue-also ultimately affect patients' access to care. 1
7
Priority-setting decisions can markedly affect the ability of the healthcare system
to save lives, cure illness, and improve patients' quality of life. Directing resources
toward treatments that save more lives and cure more illnesses has had, in many cases,
a greater impact than the discovery of a new antibiotic or an innovative device.18 As
the medical ethicist Toby Ord observes:
If we can save one thousand lives with one intervention and ten thousand
with another at an equal price, then merely moving our funding from the
first to the second saves nine thousand lives. Thus merely moving
funding from one intervention to a more cost-effective one can produce
almost as much benefit as adding an equal amount of additional
funding. 19
Ord's point is that moving funding from a less cost-effective to a more cost-
effective intervention can provide almost as much benefit as increasing funding for a
more cost-effective intervention by the same amount. But his reasoning additionally
suggests that moving funding from a less cost-effective to a more cost-effective
intervention could provide more benefit than adding a lesser amount of additional
funding, or than making a modest improvement in the efficiency or effectiveness of
medical practice.
However, unlike the discovery of new antibiotics or surgical techniques, priority-
setting decisions are frequently controversial. This is because the great gains realized
by shifting resources toward more cost-effective interventions entail losses-
pharmaceutical 'formularies,' for example, whereby drugs in more favored coverage 'tiers' require lower
patient copayments, and drugs in less favored tiers require higher copayments or are even excluded from
coverage altogether.").
16 See Korobkin, supra note 15, at 549-50 ("Using an emerging practice known as value-based
insurance design ('VBID'), insurance companies and self-insured employers have experimented with
offering reduced or even zero copayments for prescription drugs that, when taken as directed, are
particularly likely to reduce future health care costs." (footnotes omitted)); see also 42 U.S.C. § 300gg-13(c)
(2012) ("The Secretary may develop guidelines to permit a group health plan and a health insurance issuer
offering group or individual health insurance coverage to utilize value-based insurance designs."); D.C.
CODE § 31-3171.16(a)(1)(A)(i)(IX) (2001) (stating that the D.C. health exchange's advisory board should
evaluate whether the exchange should employ a "[v]alue-based insurance design"); Public Comment Letter
from Mark J. Ugoretz, President, ERISA Indust. Comm., to the Internal Revenue Service (Sept. 8, 2010) (on
file with the Federal eRulemaking Portal), available at http://www.regulations.gov/#!
documentDetail;D-IRS-2010-0017-0003 (noting that the ERISA Industry Committee "strongly supports the
provisions that promote value-based insurance designs by permitting plans to impose cost-sharing
requirements on out-of-network services").
17 See MD. CODE ANN., EDUC. § 18-2805(b) (LexisNexis Supp 2014) (directing the office responsible
for student loan repayment assistance to "prioritize funding for the repayment of education loans" to
physicians practicing in underserved geographic areas or underserved specialties); VA. CODE ANN. § 32.1-
122.6 1 (Supp. 2014) (similar state code); see also Ann Marie Marciarille, Healing Medicare Hospital
Recidivism: Causes and Cures, 37 AM. JL. & MED. 41, 69 (2011) ("The shortage of primary care physicians
is itself partly a payment systems failure that rewards specialists with much higher incomes-and
concomitantly much higher professional status-than that accorded primary care physicians."); Thomas
Win. Mayo, Nonfinancial Barriers to Health Care, 32 HOUS. L. REV. 1187, 1188-89 (1996) (discussing how
geographic and specialty mal-distribution among Texas physicians presents a barrier to healthcare access).
"8 See TOBY ORD, THE MORAL IMPERATIVE TOWARD COST-EFFECTIVENESS IN GLOBAL HEALTH 7
(2013), available at www.cgdev.org/content/publications/detail/1427016 (illustrating the magnitude of the
impact that reallocation of resources can have on saving lives).
19 Id.
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sometimes substantial losses-for those who benefited from the less cost-effective
interventions. 20 Put differently, priority-setting decisions, unlike medical innovations,
are not Pareto improvements. 21 Those who believe they will lose under a given
priority-setting regime frequently organize to oppose that change, even when their
22victory leads to a less effective healthcare system. Consider, for example, Ord's
suggestion that the money spent on providing surgical treatment for Kaposi's sarcoma,
a cancer associated with AIDS, could save far more lives if instead spent on expanding
access to antiretroviral treatments for HIV-infected individuals. 23 A proposal to put
Ord's suggestion into practice would almost certainly draw fire from those who have a
stake in continued public funding for the treatment of Kaposi's sarcoma: patients with
the condition, surgeons specializing in its treatment, and associated advocacy
organizations. This coalition might mobilize to entrench funding for Kaposi's sarcoma
treatment and safeguard it against attempts to shift resources toward more cost-
effective treatments, just as other groups-such as breast cancer patients, 24 back
surgeons, 25 and Medicare recipients26-now do. Indeed, breast cancer advocacy groups
have already succeeded in entrenching access to mammograms in the ACA, despite
research calling mammography's clinical effectiveness into doubt.27 That priority
setting in medical care is more difficult to implement than innovation mirrors similar
phenomena elsewhere: while efforts to eliminate government fraud and abuse are
20Id. at 4-5.
21 See, e.g., Willingham v. NovaStar Mortgage, Inc., No. 04-CV-2391, 2006 WL 6676801, at *19
(W.D. Tenn. Feb. 7, 2006) ("Pareto efficiency (or optimality) occurs when no individual can be made better
off without making another worse off."); Stephen E. Ellis & Grant M. Hayden, The Cult of Efficiency in
Corporate Law, 5 VA. L. & BUS. REv. 239, 241-42 (2010) ("A situation x is a Pareto improvement over a
situation y just in case no one (strictly) prefers y to x and at least one person (strictly) prefers x to y .... The
uncontested nature of Pareto improvements is what makes them so appealing to economists. So long as a
given situation is a Pareto improvement over what preceded it, one never has to balance one person's gains
in satisfaction with another's losses .... " (footnote omitted)).
22 Cf Timothy Stoltzfus Jost & Sandra J. Tanenbaum, Selling Cost Containment, 19 AM. JL. & MED.
95, 95 (1993) ("As long as the health care system reform debate is cast as a zero-sum game, under which the
current 'winners' in health care will either continue to 'win' or become 'losers,' the concentrated special
interests that benefit from high health care costs will continue to obstruct change.").
23 ORD, supra note 18, at 2.
24 See Nan D. Hunter, Rights Talk and Patient Subjectivity: The Role of Autonomy, Equality, and
Participation Norms, 45 WAKE FOREST L. REv. 1525, 1543 (2010) (noting that "advocates obtained... [a]
provision in legislation that established breast cancer research in the Department of Defense ('DoD'), a
location that insulated it from cuts in domestic funding that customarily exempted DoD.").
2 See Sofamor Danek Grp. v. Gaus, 61 F.3d 929, 931 (D.C. Cir. 1995) (challenging federal clinical
practice guidelines), cert. denied, 516 U.S. 1112 (1996); Eleanor D. Kinney, Behind the Veil Where the
Action Is: Private Policy Making and American Health Care, 51 ADMIN. L. REv. 145, 167 (1999) (detailing
Congress's efforts to defund the agency responsible for promulgating clinical practice guidelines on
treatment of back pain).
26 See April M. Elliott, Note, Medicare as Technology Regulator: Medicare Policy's Role in Shaping
Technology Use and Access, 26 BERKELEY TECH. LI. 1489, 1506-07 (2011) (noting that "changes to the
fundamental nature of Medicare and to the guarantee of coverage it provides to millions of beneficiaries are
widely considered politically infeasible"); see also Michael F. Cannon, Pay-for-Performance: Is Medicare a
Good Candidate?, 7 YALE J. HEALTH POL'Y L. & ETHICS 1, 31-32 (2007) ("Given the influence that
Medicare's P4P decisions would have on providers' incomes and the overall tax burden, those interest
groups can be expected to use political pressure to block changes that they expect would adversely affect
their interests.").
2 42 U.S.C. § 300gg-13(a)(5) (2012) ("[F]or the purposes of this chapter, and for the purposes of any
other provision of law, the current recommendations of the United States Preventive Service Task Force
regarding breast cancer screening, mammography, and prevention shall be considered the most current other
than those issued in or around November 2009."); see also Jessica Mantel, Setting National Coverage
Standards for Health Plans Under Healthcare Reform, 58 UCLA L. REV. 221, 246 (2010) (noting that "the
Senate quickly amended their healthcare reform bill to include a provision guaranteeing coverage of annual
mammograms for women age forty and over").
126 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 41 NO. 12015
broadly popular, proposals to replace existing programs with more efficient
alternatives frequently meet vigorous opposition from those who would lose out due to
21the change.
The ACA, perhaps in recognition of the political power particular interest groups
wield, contains no "death panels",29 or "God Committees",3° that set specific priorities
for micro-level allocation, or that directly deny Alice, Bill, or Caroline access to
treatment. Nonetheless, the ACA's provisions substantially affect the priorities that
physicians, insurers, and other actors in the healthcare system pursue. By establishing
which priority-setting factors may be used in establishing the list of essential health
benefits,31 the ACA shapes the landscape of medical care: if a category of treatments is
defined as an essential health benefit, that category of treatments will be provided in
32every plan that is a "qualified health plan' under the ACA. The same is true when the
ACA sets standards for which factors can be employed in priority setting within
Medicare. 33 The ACA also establishes-and establishes priority-setting standards
for-the PCORI, which researches the comparative effectiveness of different
treatments and publicizes its findings, thereby providing physicians and insurers with
an important resource when setting priorities. 34 And the ACA regulates plans offered
through government-established Health Insurance Exchanges ("Exchanges") in other
ways; for instance, the ACA requires plans to permit enrollees to participate in certain
clinical research trials.35
Part II discusses in more detail these provisions of the ACA, which explicitly set
healthcare priorities, or-more frequently-prohibit decision makers from considering
certain factors when setting priorities.
III. HEALTH CARE PRIORITIES IN THE ACA
Many aspects of the ACA simply attempt to improve cost, quality, or access to
healthcare for patients across the board, by increasing funding or focusing resources on
28 See Corinna Sorenson et al., The Politics of Comparative Effectiveness Research: Lessons from
Recent History, 39 J. HEALTH POL. POL'Y & L. 139, 153 (2014) ("[I]n both the United States and abroad, a
public backlash has occurred when available evidence calls for some degree of disinvestment or places
conditions on access to or payment for care. In such cases, the research (and general overall approach) is
seen as a potential threat to the interests of vested stakeholders, namely, organized medicine, industry, and
patient advocacy organizations-groups who typically possess significant resources to influence policy
makers."); cf David A. Hyman, Convicts and Convictions: Some Lessons from Transportation for Health
Reform, 159 U. PA. L. REV. 1999, 2024 (2011) (quoting Laura Meckler, Obama's Health Expert Gets
Political, WALL ST. J., July 24, 2009, at Al) ("Officials had been trying for years to cut payments to
suppliers of oxygen and other medical equipment, which critics say are inflated. Yet when a new
competitive bidding process was set to take effect last year, industry supporters in Congress were able to
delay the plan. They are still fighting to block changes.").
29 See Bank of America Corp., SEC No-Action Letter, 2011 WL 87736 (Mar. 7, 2011) (discussing the
"protests over 'death panels' that supposedly would result from health care reform legislation"); Abigail R.
Moncrieff, The Freedom of Health, 159 U. PA. L. REv. 2209, 2239-41 (2011) (recapping the "death panels"
debate).
30 See Sallie Thieme Sanford, What Scribner Wrought: How the Invention of Modern Dialysis Shaped
Health Law and Policy, 13 RICH. JL. & PUB. INT. 337, 341-42 (2010) (discussing how a committee
responsible for selecting patients to receive life-saving treatment was dubbed the "God Committee")."' 42 U.S.C. § 18022 (2012).
32 42 U.S.C. § 18021(a)(1)(B).
" See 42 U.S.C. § 1320e-l(c)-(e).
14 42 U.S.C. § 1320e(b)-(d).
" 42 U.S.C. § 300gg-8(d)(1) ("'[A]pproved clinical trial' means a phase I, phase II, phase III, or phase
IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-
threatening disease or condition.").
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36preventing fraud and waste. Although these aspects may incidentally affect priority
setting, their focus is not the distribution of benefits among patients.37
This Article, in contrast, concentrates on provisions in the ACA that explicitly
prohibit or require certain forms of priority setting, and thereby affect the comparative
priority that specific health conditions-like those of Alice, Bill, and Caroline-
receive in the healthcare system. The provisions I discuss in this Part pertain to four
different aspects of the healthcare system that the ACA establishes or affects: PCORI,
Medicare, essential health benefits, and the Exchanges. These provisions restrict the
use of four different health factors for priority setting: disability, age, life expectancy,
and imminence of death.38
Disability Age Future Life Imminence of
Expectancy Death
PCORI Prohibited Permitted Permitted Permitted
Medicare Prohibited Prohibited Prohibited Permitted
Essential Health Prohibited Prohibited Prohibited Permitted
Benefits
Exchange Plans Neutral Neutral Neutral Required
I divide my discussion below into four subparts, focusing on PCORI, Medicare,
essential health benefits, and Exchanges, respectively. I choose this organization,
rather than organizing my discussion by health factor, in order to emphasize that the
ACA issues different guidelines to different actors within the healthcare system. That
the ACA directs one actor, like PCORI, to consider or ignore a given healthcare factor
when setting priorities does not entail that it gives the same direction to another actor,
like Medicare.
Interestingly, many of the provisions in the ACA that prohibit or require certain
forms of priority setting represent an unusual consensus among a variety of actors in
the healthcare system. Many were added through efforts by conservative Senators who
opposed the ACA, such as Michael Enzi of Wyoming, and conservative lobbying
organizations such as the National Committee on the Right to Life.39 Yet they have
been embraced by many more moderate and liberal causes, such as patient advocacy
groups and advocates for persons with disabilities. 40 They have also met approval from
36 E.g., 42 U.S.C. §§ 300gg-1 7 to -18 (designating the subheadings as "Ensuring the quality of care"
and "Bringing down the cost of health care coverage," respectively).
17 See 42 U.S.C. § 300gg-17.
38 See 42 U.S.C. § 1320e-1(c)(1) ("The Secretary shall not use evidence or findings from comparative
clinical effectiveness research conducted under section 1320e of this title in determining coverage,
reimbursement, or incentive programs under subchapter XVIII of this chapter in a manner that treats
extending the life of an elderly, disabled, or terminally ill individual as of lower value than extending the life
of an individual who is younger, nondisabled, or not terminally ill."); 42 U.S.C. § 18022(b)(4)(B) (listing the
required elements for consideration in defining essential health benefits); 42 U.S.C. § 1803 1(e)(1)(B)(iii)
(explaining how an Exchange may certify a health plan as a qualified health plan).
" See John K. Iglehart, The Political Fight over Comparative Effectiveness Research, 29 HEALTH AFF.
1757, 1758 (2010); Sorenson et al., supra note 28, at 142 (discussing Republican opposition to
"considerations of cost or cost-effectiveness in the research").40 E.g., 156 Cong. Rec. E462-63 (daily ed. Mar. 23, 2010) (statement of Rep. Pascrell) (describing
some of the restrictions as "strong protections that will help ensure that the essential health benefits package
... will take into account the needs of people with brain injury and other disabilities ... and not impose
value judgments about disability and quality of life."); SARA ROSENBAUM ET AL., THE ESSENTIAL HEALTH
BENEFITS PROVISIONS OF THE AFFORDABLE CARE ACT: IMPLICATIONS FOR PEOPLE WITH DISABILITIES 9
(2011) ("The Affordable Care Act's essential benefits nondiscrimination provisions break new ground in
how to think about . . . common techniques of health benefit design and management-adding new
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industry groups. 41 This complicates any sort of purposive or public meaning
interpretation of these provisions. Looking to the intent of the legislators who
introduced the provision might suggest an interpretation in line with conservative
objections to cost-effectiveness, which have emphasized concerns about ill people-
particularly the elderly-being deprived of opportunities to access costly, last chance
42treatments. The public understanding of the statute, however, suggests that these
provisions also benefited from support on more traditionally liberal grounds. These
grounds include concerns about health insurers cherry-picking healthy patients, about
the fair treatment of people with disabilities, and about ensuring that the health
benefits offered through the ACA were valuable to a diverse cross section of the
population. 43
Some have argued that the provisions I will discuss below in fact place few
meaningful restrictions on the use of standard methods of priority setting, such as the
use of quality-adjusted life years.44 This argument has come both from those
enthusiastic about the believed lack of restriction and those concerned about it.
Stephen Mikochik argues that the ACA broadly permits priority-setting methods that
disadvantage people with disabilities:
Of the numerous instances where the Act authorizes adoption of quality
measures, in one case only is the Secretary of Health and Human
Services expressly forbidden from relying on comparative clinical
effectiveness research that discounts the lives of disabled people. No
comparable limit prevents the use of such research in developing best
practices for the delivery of health care services. Even in formulating a
national health care strategy, the Secretary is not prohibited from
dimensions to prior federal laws regulating insurance and health plans and barring discrimination.");
CONSORTIUM FOR CITIZENS WITH DISABILITIES, IOM ESSENTIAL HEALTH BENEFITS SURVEY RESPONSES 10
(praising the restrictions on considering disability within comparative effectiveness research as "very
powerful language that is designed to ensure that normative judgments about the quality of life of a person
with a disability are not used against people with disabilities when decision makers determine the essential
benefits package"); Letter from the Habilitation Benefits Coal., to Marilyn Tavenner, Adm'r, Ctrs. for
Medicare & Medicaid Servs. (Feb. 21, 2013) (on file with the Children's Hospital Association), available at
http://www.aahd.us/wp-content/uploads/2013/02/HABCoalitonLtrMedicaidO22 12 0 1 3 .pdf (similar); Letter
from Susan Henderson, Exec. Dir., Disability Rights Educ. & Def. Fund, to Kathleen Sebelius, Sec'y, U.S.
Dep't of Health & Hum. Servs. (Feb. 14, 2012) (on file with author) (similar).
4' Letter from Orthotic & Prosthetic Alliance, to Gary Cohen, Dir., Ctr. for Consumer Info. & Ins.
Oversight (Dec. 26, 2012) (on file with author), available at available at
http://www.oandp.org/assets/PDF/EHB Comments D0454932-2.pdf. (endorsing prohibition on excluding
coverage for services based on age, disability, or length of life); Press Release, Pharmaceutical Research &
Mfrs. of Am., Statement of the Pharmaceutical Research and Manufacturers of America Supporting Oregon
SB 1565 (Jan. 30, 2014) (on file with author), available at http://web.archive.org/web/
2015 03 23 7 55 6/https: olis.leg.state.or.us/liz/20 14RI /Downloads/CommitteeMeetingDocument/3 2029
("The Pharmaceutical Research and Manufacturers of America (PhRMA) and its member companies
strongly support the provisions of federal law that prevent discrimination based on age, expected length of
life, present or predicted disability, degree of medical dependency or quality of life.").
42 Cf John A. Robertson, Cruzan and the Constitutional Status of Nontreatment Decisions for
Incompetent Patients, 25 GA. L. REV. 1139, 1140 (1991) ("From the vitalist perspective, all human life is
viewed as worthy of protection regardless of its quality or functional ability.").
41 See HENRY J. KAISER FAMILY FOUND., KAISER HEALTH TRACKING POLL: MARCH 2013, 8-9 (2013),
available at http://kff.org/health-reform/poll-finding/march-2013-tracking-poll/; ROSENBAUM ET AL., supra
note 40, at 3-4, 11-12; Michael Saks, What Do Polls Really Tell Us Care Act?, HEALTH AFF. BLOG (Sept.
21, 2012, 11:42 AM), http://healthaffairs.org/blog/2012/09/21/what-do-polls-realy-tell-us-about-the-
public s-view-of-the -affordable -care -act!.
44 See, e.g., Nicholas Bagley, Bedside Bureaucrats: Why Medicare Reform Hasn't Worked, 101 GEO.
L.J. 519, 574 (2013) ("As a practical matter, none of the Medicare-specific prohibitions appear all that
constraining."); Mikochik, supra note 7, at 204-05.
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incorporating the findings of biased research when addressing gaps in
comparative effectiveness information. 45
Mikochik views this broad permission as catastrophic, and argues for additional
regulation. 46 Meanwhile, Nicholas Bagley agrees with Mikochik that the ACA places
few restrictions on the use of cost-effectiveness analysis, but regards this as a desirable
feature of the ACA.47 Others have argued that the ACA substantially limits or entirely
prohibits the use of cost-effectiveness analysis in the healthcare system. 48
The truth is somewhere in between. The ACA does place substantial limitations
on the use of traditional cost-effectiveness analysis by certain actors in the healthcare
system, and also fails to remove the limitations that other laws-most notably the
Americans with Disabilities Act (ADA)-may place on cost-effectiveness analysis,
particularly on methods that employ quality-adjusted life years (QALY) as a metric.
But the ACA is not invariably hostile to the use of cost-effectiveness or comparative
effectiveness information, so long as these approaches are employed without
considering certain factors in a prohibited way.49 Furthermore, different sections of the
ACA limit the use of cost-effectiveness information in different ways. The limitations
on the use of cost-effectiveness information to set essential health benefits, for
instance, are more restrictive than the limitations on its use in PCORI or in Medicare.50
I turn now to a discussion of these individual sections.
A. THE PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
51The ACA establishes, and provides funding for, the PCORI. PCORI is a
nonprofit corporation whose core aim "is to assist patients, clinicians, purchasers, and
,52policy-makers in making informed health decisions." The ACA directs PCORI to
pursue that aim by researching the comparative risks and benefits of different
treatments, and by disseminating its research findings to healthcare decision makers.53
PCORI does not issue mandates; rather, it provides information that decision makers
can rely on as they set priorities.54
Although PCORI has been praised as a potential lever to limit high-cost, low-
benefit care,55 the ACA limits the approach to priority setting that PCORI can take.
Although the initial draft of the ACA authorized PCORI to assess "efficiency and
value (including the full range of harms and benefits, such as quality of life)," 56 this
41 Mikochik, supra note 7, at 204-05.
4 6 Id. at 205.
4' Bagley, supra note 44, at 574.
4' E.g., Barry R. Furrow, Cost Control and the Affordable Care Act: CRAAJPing Our Health Care
Appetite, 13 NEV. L.J. 822, 853 (2013); Lawrence 0. Gostin et al., Restoring Health to Health Reform:
Integrating Medicine and Public Health to Advance the Population's Well-Being, 159 U. PA. L. REV. 1777,
1779 (2011); Elizabeth Weeks Leonard, Death Panels and the Rhetoric of Rationing, 13 NEV. L.J. 872, 885
(2013); Sorenson et al., supra note 30, at 142 ("[T]he bill language prohibited the use of quality-adjusted life
years (QALYs), a metric used in cost-effectiveness to measure net health gain.").
49 Thomas J. Parisi, How Much Did You Pay for Your Heart: Is a Centralized Entity Performing
Health Technology Assessment with Cost-Effectiveness Analysis the Answer to the Rising Costs of Health
Care?, 49 JuRIMETRiCS 285, 299 (2009).
'0 See Furrow, supra note 48, at 853.
42 U.S.C. § 1320e(b) (2012).
2 42 U.S.C. § 1320e(c).
42 U.S.C. § 1320e(d)(1)(A).
14 42 U.S.C. § 1320e(b).
" See Barry R. Furrow, Regulating Patient Safety: The Patient Protection and Affordable Care Act,
159 U. PA. L. REv. 1727, 1738-39 (2011).16 James Dabney Miller, The Patient-Centered Outcomes Research Institute, 4 J. HEALTH & LIFE SC.
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mandate disappeared in the final version of the ACA. 57 Instead, 42 U.S.C. § 1320e-
l(e) mandates that, PCORI "shall not develop or employ a dollars-per-quality adjusted
life year (or similar measure that discounts the value of a life because of an
individual's disability) as a threshold to establish what type of healthcare is cost
effective or recommended., 58
Many commentators have worried that section 1320e-l(e) eviscerates PCORI's
ability to engage in any sort of analysis that considers costs as well as comparative
effectiveness. 59 Barry Furrow, for example, argues that this section of the statute
imposes "a prohibition on cost-effectiveness calculations" on PCORI, and "appears to
explicitly block study of a treatment's cost-effectiveness.",60 Elizabeth Weeks Leonard
similarly notes that "PCORI is prohibited from generating QALY data, which
commercial insurers, providers, and patients might use to compare cost effectiveness
of treatment alternatives just as the President envisioned. ,61 And Larry Gostin and his
co-authors note, "the final law inhibits the use of quality cost-effectiveness analysis in
coverage, reimbursement, and incentive structures.",62 I will argue that the ACA's
limitation on the use of QALYs within PCORI does not announce a broad opposition
to consideration of costs in priority setting, but rather pursues a more narrow aim: to
ensure that patients with preexisting disabilities (like our osteosarcoma patient
Caroline) are not disadvantaged in priority-setting decisions on the basis of the effect
of their preexisting disability on their future quality of life.
Although the statute establishing PCORI defines several other terms, 63 it does not
define a "quality-adjusted life year.",64 However, QALYs are widely used by health
economists when assessing the benefit of a medical or public health intervention or the
65 66burden of an illness, and have been proposed for use by agencies as well. As John
La Puma notes, "QALYs attempt to combine expected survival with expected quality
of life into a single number: if an additional year of healthy life expectancy is worth a
value of one (year), then a year of less healthy life expectancy is worth less than one
(year).",67 For example, if amputating Caroline's leg to protect her from osteosarcoma
will extend her life by fifty years, but will reduce her quality of life during thoseadditional years to 70% of a fully healthy person's quality of life, then a QALY
L. 4, 19 (2010) (quoting Patient-Centered Outcomes Act of 2009, S. 1213, 11 1th Cong. § 2(a) (2009)).
17 Id.; see 42 U.S.C § 1320e-l(e) (2012).
" 42 U.S.C. § 1320e-l(e).
'9 See sources cited supra note 48.
60 Furrow, supra note 48, at 853.
61 Leonard, supra note 48, at 885.
62 Gostin et al., supra note 48, at 1779.
63 See 42 U.S.C. § 1320e(a) (2012).
64 See id.
61 See, e.g., C.C. Earle et al., Systematic Overview of Cost-Utility Assessments in Oncology, 18 J.
CLINICAL ONCOLOGY 3302, 3302-03 (2000).
66 H.R. 2101, 112th Cong. § 39900(b)(1) (2013) (proposing "a Center of Eating Disorders
Epidemiology for the purpose of," inter alia, "collecting and analyzing information on the effects of eating
disorders on quality of life, including disability adjusted life years (DALY) and quality-adjusted life years");
OFFICE OF MGMT. & BUDGET, ExEC. OFFICE OF THE PRESIDENT, OMB CIRCULAR NO. A-4, REGULATORY
ANALYSIS (2003) (discussing comprehensive, integrated measures of effectiveness such as the number of
equivalent lives (ELs) saved and the number of QALYs saved). International organizations use a similar
measure, the disability-adjusted life year (DALY), to make funding and practice recommendations for
medical care worldwide. See, e.g., Nuria Homedes, The Disability-Adjusted Life Year (DALY) Definition,
Measurement and Potential Use 1 (World Bank, Human Capital Working Paper No. 16128, 1996), available
at http://documents.worldbank.org/curated/en/1996/07/696380/disability-adjusted-life-year-daly-definition-
measurement-potential-use.
67 John La Puma, Quality-Adjusted Life Years: Ethical Implications and the Oregon Plan, 7 ISSUES L.
& MED. 429, 429 (1992).
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approach will evaluate the procedure as providing thirty-five QALYs (fifty life years
at a quality of life of 0.7).
The appeal of the QALY is that it provides a single, unified way of accounting for
the effects of medical interventions on both quality and length of life. As Matthew
Adler has noted, a variety of administrative agencies have recently employed QALYs,
or related units of measurement that consider an intervention's effect on both quality
and length of life, when making regulatory decisions:
The FDA, over the last half-decade or so, has repeatedly relied on
QALYs in its mlemakings .... [T]he EPA has experimented with the
so-called "value of statistical life year" (VSLY) approach to monetizing
mortality, an approach closely related to QALYs .... The HHS, in a
recent rulemaking facilitating flu and pneumonia vaccinations, cited the
cost-effectiveness of these vaccinations in promoting "year[s] of healthy
life," a synonym for a QALY. The Office of Management and Budget's
(OMB) current guide for Executive Order 12,866, which requires formal
regulatory analyses of major rules, stipulates that these documents must
include a cost-effectiveness analysis in the case of rules targeted at
public health and safety, and it gives a qualified endorsement to QALYs
as an appropriate effectiveness metric. The Public Health Service's
"Healthy People" initiative, an informational program which measures
progress towards public health goals, employs QALYs as one of its key
metrics.68
The ACA's explicit rejection of the use of QALYs diverges from the programs Adler
mentions, and raises the question of what lies behind the ACA's choice not to employ
a QALY approach.
Determining how much a given disability detracts from quality of life is often
done by employing a "time trade-off' design, where people are asked how much future
61life they would give up in order to live that future life without disability. Such time
trade-off questions can be posed both to non-disabled and disabled people: non-
disabled people could be asked how much extra life would compensate for suffering a
disability, while disabled people could be asked how much life they would give up in
order to be cured of a disability. However, time trade-offs arguably confuse two types
of questions: what ethicists call "axiological questions" (questions about which options
produce the most benefit), and what they call "deontic questions" (questions about
which options we ought to choose). 70 That Caroline regards forty-five years of life
without a hearing impairment as personally preferable to fifty years of life with a
hearing impairment does not entail that she regards it as good public policy to
disadvantage someone with an incurable hearing impairment when deciding who
should receive life-extending treatment. Yet QALY approaches give lower priority to
extending the lives of already disabled people. This objection to QALYs may have
found expression-in dicta-in one recent case, where the D.C. Circuit suggested that
cost-effectiveness analysis should adopt an approach that, for policy purposes, treats
disadvantages imposed on people with preexisting disabilities the same as
disadvantages imposed on people without disabilities, even if the existence of a
68 Matthew D. Adler, QALYs and Policy Evaluation: A New Perspective, 6 YALE J. HEALTH POL'Y L.
& ETHICS 1, 4-6 (2006).6 91d. at 1-3.
" For this distinction, see, for example, Dale Jamieson, Climate Change, Consequentialism, and the
RoadAhead, 13 CHI. J. INT'L L. 439, 458 (2013).
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preexisting disability means that the disadvantage does not result in as great a change
in well-being.7 1
The ACA's reason for prohibiting PCORI from using QALYs as a threshold
reflects this concern. The language of section 1320e-l(e), which refers not only to
QALYs but also to any "similar measure that discounts the value of a life because of
,72an individual's disability," indicates that QALYs are prohibited as part of a more
general prohibition on the use of any method of measurement that treats extending a
person's life as a lower priority when that person suffers from a disability than when
she does not.
While PCORI does not make direct prescriptions about which individual patients
should receive care, permitting PCORI to use QALYs could disadvantage persons with
disabilities in at least two ways. First, other actors in the healthcare system might rely
on PCORI's QALY-based recommendations when setting priorities for coverage,
reimbursement, or incentives. For instance, life-extending treatments for people who
frequently have other comorbidities might receive lower priority than life-extending
treatments offered to healthy people. Second, PCORI-as a creation of federal law-
might expressively indicate a governmental endorsement of the view that extending
the life of people with disabilities is a lower priority than extending the lives of others.
The objection that the ACA disadvantages people with disabilities is ambiguous in
at least one important way. Return to the two ways that QALYs consider the quality of
life that treating Caroline would produce. First, they consider limitations on quality of
life that result from disabilities-such as her hearing impairment-that preexist the
treatment she receives. Second, they consider limitations that result from disabilities,
such as an amputated leg, that treating her would cause. When responding to Oregon's
use of QALYs in Medicaid, HHS also identified the consideration of disabilities
caused by treatment as objectionable, arguing that the Oregon plan, by giving higher
priority to treatments that improved quality of life as well as extending life than to
treatments that extended life without improving quality, disadvantaged people with
disabilities. 73 In contrast, section 1320e-l(e) explicitly differentiates preexisting
disabilities from those that result from treatment, and permits PCORI to consider the
way that treatment affects future quality of life:
Nothing in the provisions of, or amendments made by the Patient
Protection and Affordable Care Act, shall be construed to limit
comparative clinical effectiveness research or any other research,
evaluation, or dissemination of information concerning the likelihood
that a health care treatment will result in disability.74
This "result in disability" provision differentiates the treatment of preexisting
disability from that of treatment-caused disability .7 It permits PCORI to consider the
fact that treating Caroline's osteosarcoma will mean the loss of her leg, even when it
directs comparative effectiveness research to ignore the fact that Caroline is
antecedently hearing impaired.
7 Am. Trucking Ass'ns v. U.S. Envtl. Prot. Agency, 175 F.3d 1027, 1039 n.5 (D.C. Cir. 1999)
(proposing "measuring the seriousness of a pollution-induced health effect by the absolute level of well-
being that the effect brings about, not by the decrease in level that the effect causes"), affd in part, rev'd in
part sub nom. Whitman v. Am. Trucking Ass'ns, 531 U.S. 457 (2001).
72 42 U.S.C. § 1320e-l(e) (2012).
71 See Maxwell J. Mehlman et al., When Do Health Care Decisions Discriminate Against Persons with
Disabilities?, 22 J. HEALTH POL. POL'Y & L. 1385, 1396 (1997).
74 42 U.S.C. § 1320e-l(d)(3) (2012).
75 id.
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Additionally, as I discuss in the next subpart, the "result in disability" provision
permits the Medicare program to consider the effect of disability on treatment
effectiveness. As such, it would permit consideration of the fact that Bill's terminal
cancer would make many treatments ineffective for him. Rather than requiring
healthcare priority setting to entirely ignore cost-effectiveness or ignore disability,
section 1320e-l(e) rejects a specific aspect of QALY analysis: that QALY-based
approaches systematically disadvantage those who are already disabled even when
setting priorities for treatment unrelated to their disability."
My approach diverges from Nicholas Bagley's suggestion that PCORI may
employ a QALY-based approach, even one that disadvantages people with disabilities,
so long as it does not use QALYs as a threshold. Bagley has argued that the ACA
permits PCORI to rank treatments by their cost-per-QALY, or to incorporate QALYs
as one consideration in a system of priority setting, so long as PCORI's priority-setting
arrangement considers other factors as well. Bagley's suggestion that QALYs may
be used so long as they are not used as a strict threshold 7-parallels other efforts to
continue considering a controversial factor so long as that factor does not represent the
only reason for a given decision. The most obvious parallel is the use of race and
ethnicity in employment and admissions decisions. 9 In Grutter v. Bollinger, the
Supreme Court held that while a quota system that requires that a specific number of
seats be set aside for minority applicants was constitutionally unacceptable because it
permitted race to function as the sole factor determining whether an applicant was
admitted, it was acceptable to "consider race or ethnicity more flexibly as a 'plus'
factor in the context of individualized consideration of each and every applicant." '
Following Grutter, many universities shifted to holistic review, and were able to
continue considering race as part of an effort to ensure a diverse student body."'
However, courts and others interpreting the ACA do so in a different context than
that of cases like Grutter. Grutter considers whether a state statute can consider race
without violating the Constitution, 82 whereas those interpreting the ACA will be
evaluating not whether considering disability status would be unconstitutional, but
rather whether doing so is a faithful interpretation of the statute. Cases construing the
ADA have resisted allowing disability status to be a disadvantaging factor in
employment, even when disability status is not the sole factor underlying the
employer's choice."' A recent Sixth Circuit en banc decision established that no
federal circuit court now requires, for relief under the ADA, that an employee's
disability be the "sole factor" underpinning an employer's decision to fire an
814employee. In the Sixth Circuit, relief can now be granted in cases where the disability
is a "but for" factor, 85 while other circuits go further, granting relief in cases where the
76 42 U.S.C. § 1320e-l(e); see also Bagley, supra note 44, at 573-74.
77 Nicholas Bagley, Who Says PCORI Can't Do Cost Effectiveness?, INCIDENTAL ECONOMIST (Oct.
14, 2013, 6:00 AM), http://theincidentaleconomist.com/wordpress/who-says-pcori-cant-do-cost-
effectiveness/; see also Bagley, supra note 44, at 574.
7' Bagley, supra note 44, at 574.
71 See, e.g., Grutterv. Bollinger, 539 U.S. 306 (2003).
80 Id. at 334.
Sung Hui Kim, The Diversity Double Standard, 89 N.C. L. REv. 945, 975 (2011) (noting that "the
University of Michigan's undergraduate admissions office hired additional application counselors and
readers, at a cost of $1.8 million, to move to a system of holistic review of application files.").
82 Grutter, 539 U.S. at 321-22.
3 See, e.g., Lewis v. Humboldt Acquisition Corp., 681 F.3d 312, 321 (6th Cir. 2012).
84 Id. at 315.
Id. at 321.
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disability is a "motivating factor.",16 Although the ACA's treatment of disability is not
identical to that of the ADA, cases interpreting the ADA indicate that objections to the
use of a factor or procedure that disadvantages people with disabilities can apply even
when the disadvantaging factor is only one among many other factors. 7
Ultimately, although Bagley's employment of the "threshold" language is an
inventive attempt to continue using QALYs as one factor among many, I do not
believe the "threshold" language decisively establishes that PCORI may use QALYs-
even as one factor among many-without violating prohibitions on discrimination
against people with disabilities. Courts interpreting the "threshold" language may
instead construe the statute to prohibit at least some uses of QALYs where QALY
factors play a substantial role in the ultimate recommendation.88 Furthermore, the
sections below indicate that restrictions on the use of QALYs elsewhere in the ACA
would prohibit their use-as currently conceived-entirely, at least in some cases,
which may lead courts to prohibit PCORI from using QALYs as well." In contrast, as
I will discuss in Part III, adopting a method of cost-effectiveness analysis that avoids
disadvantaging people with preexisting disabilities would avoid violating the
restrictions that the ACA places on PCORI.
B. MEDICARE
The ACA also prohibits certain forms of priority setting within the Medicare
program. Section 1320e-l(e) provides that Medicare may not use QALYs or similar
factors that disadvantage people with preexisting disabilities "as a threshold to
determine coverage, reimbursement, or incentive programs." 90 Meanwhile, section
1320e-1(c)(1) specifies that:
The Secretary shall not use evidence or findings from comparative
clinical effectiveness research conducted under section 1320e of this title
[i.e., by PCORI] in determining coverage, reimbursement, or incentive
programs under subchapter XVIII in a manner that treats extending the
life of an elderly, disabled, or terminally ill individual as of lower value
than extending the life of an individual who is younger, nondisabled, or
not terminally ill.91
Section 1320e-1(c)(1) requires that three defined groups not be disadvantaged in
priority setting within Medicare: the elderly, the disabled, and the terminally ill.92 The
protection of each group, as I argue next, poses a unique challenge to priority setting.
Giving equal priority to people with disabilities limits the use of QALY approaches;
giving equal priority to the elderly limits the use of age weighting; and giving equal
86 Id. at 324-25 (Clay, I., concurring in part and dissenting in part) (collecting cases).
17 See id. at 323-35.
" Cf Ogdenv. Bureau of Labor, 699 P.2d 189, 191 (Or. 1985) ("If the word 'solely' ... were given its
literal meaning, forbidden age discrimination would occur only if age were the 'sole factor' in an
employment decision, that is to say, only if the employer's explicit or actual policy were to give preference
to an older or a younger employee without regard to any other characteristic, qualification, or performance.
The commissioner is not bound to so limited a view of the law.").
89 Cf Heslop v. Sanderson, 123 S.W.3d 214, 222 (Mo. Ct. App. 2003) (noting "the illogical result that
although home schooling could not be considered as the sole factor in determining whether a custodial
arrangement was in the child's best interests, it could be considered as a change of circumstance to modify
custody").
90 42 U.S.C. § 1320e-l(e) (2012).
9' 42 U.S.C. § 1320e-1(c)(1). Subchapter XVIII is the section of the United States Code that provides
the framework for Medicare.
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priority to terminally ill people may-although I argue it ultimately does not-limit
the use of any approach that considers a patient's future lifespan.
1. Individuals with Disabilities
Section 1320e-1(c)(1) clearly prohibits Medicare from considering additional
years of life for a person with disabilities as less valuable than additional years of life
for a non-disabled person.93 It therefore prohibits the use of QALYs to determine"coverage, reimbursement, or incentive programs" within Medicare. Furthermore, it
goes beyond section 1320e-l(e)'s restriction on the use of QALYs in PCORI and
Medicare, because it prohibits all priority-setting methods for life-extending
treatments that give lower priority to people with disabilities, rather than merely
prohibiting their use as a threshold. 94
Therefore, even if integrating QALYs into a multi-factor system for setting
priorities could permit their use within PCORI, as Bagley argued, section 1320e-
l(c)(1) would still prohibit their use within Medicare. So long as any aspect of a
priority-setting approach gives lower priority to providing a year to someone with a
disability than providing a year to someone not disabled, that approach violates section
1320e-1(c)(1). 9'
However, section 1320e-1(c)(1) does not entirely prohibit cost-effectiveness or
comparative effectiveness research from considering whether someone is disabled. In
particular, the statute permits consideration of the alternative to QALYs I discuss
above and develop further in Part III-an approach that focuses on future life years
and ignores quality of life. The permission to consider future length of life comes from
section 1320e-l(c)(2)(A), which notes that section 1320e-1(c)(1)
shall not be construed to-(i) limit the application of differential
copayments under subchapter XVIII of this chapter [i.e., Medicare]
based on factors such as cost or type of service; or (ii) prevent the
Secretary from using evidence or findings from such comparative
clinical effectiveness research in determining coverage, reimbursement,
or incentive programs under such subchapter based upon a comparison
of the difference in the effectiveness of alternative health care treatments
in extending an individual's life due to that individual's age, disability, or
terminal illness.96
This language indicates that Medicare coverage, reimbursement, and incentive
programs can consider the effect of disabilities on a treatment's effectiveness at
extending life. For instance, they can consider the fact that Bill's metastatic prostate
cancer limits the effectiveness of any healthcare treatment in extending his life when
deciding what priority for treatment he, and others with his condition, should receive.
The language of the statute, however, is ambiguous about what constitutes a
difference in effectiveness at extending life. One interpretation, which I will call the
"length-sensitive" interpretation of comparative effectiveness, would permit Medicare
to consider the effect of disability on how much additional life a treatment can be
expected to provide. For instance, if a chemotherapeutic drug has an equal chance of
extending Bill's and Alice's lives, but could extend Alice's life for more years because
her condition is less advanced, this interpretation would permit Medicare to treat Bill
93 id.
94 id.
95 id.
96 42 U.S.C. § 1320e-l(d)(2)(A).
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and Alice differently in terms of cost and reimbursement. Another interpretation, the
"length-insensitive" interpretation, would only permit Medicare to consider the effect
of disability on whether a treatment can effectively extend life. On this interpretation,
Medicare could not favor Alice over Bill in the above situation, since each has the
same chance of having his or her life extended by the treatment, even though the
number of additional years the treatment provides is longer for Alice. Nothing in the
statute compels us to choose the length-insensitive interpretation.
2. The Elderly
Section 1320e-1(c)(1) prohibits Medicare from considering additional years of life
for an elderly person as less valuable than additional years of life for a younger
person.97 This serves to prohibit the use of what medical ethicists have called "age-
weighted" theories of priority setting. 9" In its simplest form, age weighting gives
higher priority to extending the life of a younger person than it does to extending the
life of an older person by the same amount. 99 As an example, age weighting would
support treating Bill rather than Alice on the basis that Bill has enjoyed fewer years of
life than Alice has, but such an approach would be ruled out by the statute's language.
Prominent medical ethicists have defended age weighting on a variety of grounds.
Some of their arguments appeal to fairness. Robert Veatch and Alan Williams have
argued that giving a younger person priority over an older person for an extra year of
life is consistent with a more general principle of giving priority to those who have the
least of a good when distributing that good.100 That Alice has enjoyed eight cookies
while Bill has had only six, for instance, would support giving Bill the next cookie out
of the jar. Similarly, that Bill has had only six decades of life while Alice has had eight
may support giving Bill priority for additional life. The legal scholar Eric Rakowski
has similarly argued that giving priority to younger people is consistent with a
principle of equality, since doing so best equalizes people's lifespans.101 And Norman
Daniels has offered an influential argument for age weighting based on prudence when
planning one's life. 1 2 While Daniels supports a distribution similar to that proposed by
Veatch and Rakowski, he does so for different reasons. Daniels reasons that since we
all hope to live through different stages of life, we rationally should prioritize
extending our lives earlier on, so that we live to be older, over extending our lives later
on.103
Other arguments for age weighting appeal to efficiency. Daniels's colleague
Frances Kamm has speculated that years of life-like money, housing, and other
goods-may have diminishing marginal utility: each additional year of life that a
97 42 U.S.C. § 1320e-1(c)(1).
9' Aki Tsuchiya, Age-Related Preferences and Age Weighting Health Benefits, 48 SOC. SCI & MED.
267, 268-69 (1999).
99 Greg Bognar, Age-Weighting, 24 EcON. & PHIL. 167, 169 (2008); Tsuchiya, supra note 101, at 98.
Age-weighting can be combined with QALY approaches, but I focus here on age weighting applied to life
year methods that do not consider QALYs.
... Robert M. Veatch, How Age Should Matter: Justice as the Bais for Limiting Care to the Elderly, in
FACING LIMITS: ETHICS AND HEALTH CARE FOR THE ELDERLY 211, 222-23 (Gerald R. Winslow & James
W. Walters eds., 1993); see also Alan Williams, Intergenerational Equity: An Exploration of the 'Fair
Innings'Argument, 6 HEALTH ECON. 117, 117-18, 121 (1997).
1"1 Eric Rakowski, Should Health Care Be Rationed by Age?, in CONTROVERSIAL ISSUES IN AGING
103, 104-06 (Andrew E. Scharlach & Lenard W. Kaye eds., 1997).
12 NORMAN DANIELS, AM I MY PARENTS' KEEPER?: AN ESSAY ON JUSTICE BETWEEN THE YOUNG
AND THE OLD, at vii, 45-46 (1988).
'o' Id. at 53.
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person gains has less value than the preceding year. 10 4 Therefore, giving priority to
younger people produces greater benefits. 105 Some have defended more complex forms
of age weighting, which give different weights to different stages of life rather than
constantly decreasing the importance of additional life as a person grows older. Ronald
Dworkin argues that we should prioritize adolescents over both younger children and
older people, 106 while Daniel Callahan has argued that we should simply set a
threshold over which we assign no value to life extension.10 7 Meanwhile, the World
Health Organization's disability-adjusted life year approach has adopted age weighting
on the basis that an extra year for a person in the middle of their life-a person who is
more likely to be involved in caregiving or economic activity-provides more benefits
to others than an extra year of life for an older person would.108 In a recent law review
article, Sean Hannon Williams notes:
Originally, the fair innings argument split people into two groups: those
who had surpassed the average life expectancy, and those who had not.
The fair innings argument is compatible with a number of different
groupings. For example, people might deserve a chance to accomplish
certain major life milestones, each of which could be a relevant
threshold for purposes of a fair innings argument. Different people might
use different milestones, but there is likely to be widespread agreement
that children deserve a chance to develop into adults, or perhaps to have
children of their own. 109
Williams's conjecture about "widespread agreement" is supported by surveys of the
public, which frequently find some endorsement of age weighting. 110
Given the multiplicity of age-weighted approaches, section 1320e-l(c)(1)'s
prohibition on age weighting has clear significance. However, considering the
provision's context substantially complicates its effects: section 1320e-1(c)(1)
explicitly applies only to what the government can do within Medicare, which covers
primarily patients sixty-five years of age and over.111 As such, section 1320e-1(c)(1)
would not substantially interfere with Callahan's proposal, which treats benefits to
people who have lived a "natural life span" the same as middle-aged or young people,
but gives them a lower priority than benefits to middle-aged or young people.112 Most
benefits to middle-aged and young people are not provided via Medicare; the only
104 F.M. KAMM, MORALITY, MORTALITY VOLUME I: DEATH AND WHOM TO SAVE FROM IT 237-38
(1993).
10 Id. at 238.
106 RONALD DWORKIN, LIFE'S DOMINION: AN ARGUMENT ABOUT ABORTION, EUTHANASIA, AND
INDIVIDUAL FREEDOM 87 (1993).
107 DANIEL CALLAHAN, SETTING LIMITS: MEDICAL GOALS IN AN AGING SOCIETY 137-38 (1995).
108 Sudhir Anand & Kara Hanson, Disability-Adjusted Life Years: A Critical Review, 16 J. HEALTH
ECON. 685, 691-92 (1997); C.J.L. Murray, Quantifying the Burden of Disease: The Technical Basis for
Disability-Adjusted Life Years, 72 BULL. WORLD HEALTH ORG. 429, 435 (1994), available at
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2486718/pdf/bullwhoOO414-0105.pdf.
109 Sean Hannon Williams, Statistical Children, 30 YALE J. ON REG. 63, 103 (2013); id. at 123
("People care about the fact that children have more years ahead of them, but this is not necessarily all that
people care about. For example, they may care that children have not had their fair innings yet. QALYs do
not account for fair innings arguments, and thus it is reasonable to suspect that the social value of protecting
children vs. adults will be higher than indicated just by their relative remaining QALYs. This suggests that
some form of age-weighting could better align CEA with societal values regarding childhood risk
reductions." (citations omitted)). See Williams, supra note 100, for further information on the "fair innings
argument."
... See sources cited infra note 260.
... 42 U.S.C. § 1320e-1(c)(1) (2012).
112 See CALLAHAN, supra note 107, at 80-81, 118.
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individuals below sixty-five covered by Medicare are some disabled individuals and
individuals with end-stage renal disease. 113
In contrast, a prohibition on age weighting within PCORI, essential health
benefits, or the Exchanges would have swept much more broadly, but such a provision
was not enacted. Indeed, application of the expressio unius canon of statutory
interpretation would suggest that the ACA's choice to prohibit age weighting only
within Medicare permits age weighting elsewhere in the institutions governed by the
ACA.
3. The Terminally Ill
The most puzzling part of section 1320e-1(c)(1) is its choice to prohibit Medicare
from prioritizing life-extending treatments for healthier individuals over life-extending
treatments for terminally ill individuals. 114 When considered alongside section 1320e-
1(c)(2)(A), which permits the Secretary to consider the effect of terminal illness on the-'effectiveness of alternative health care treatments in extending an individual's life,"'1 15
it is not clear what exactly this prohibition entails.
If we use the length-sensitive interpretation of effectiveness, discussed above, this
prohibition simply prohibits weightings that count additional years of life for a
terminally ill person as less valuable than the same number of additional years of life
for someone not terminally ill. So it would require that the two years Bill receives
from his treatment be given the same weight as the first two years that Alice receives
from hers. But it would not prohibit priority-setting approaches that consider the fact
that Alice, because her cancer is not metastatic, can get more additional years of life
from treatment than Bill can.
In contrast, if we adopt the length-insensitive interpretation, this prohibition
requires that priority setting ignore the fact that Bill stands to gain fewer life years
from treatment, and consider only the chance that the treatment will extend his life.
Under this interpretation, considering length of life is just as objectionable as
considering quality of life. Just as section 1320e-l(c)(1)'s prohibition on
disadvantaging people with disabilities recognizes Caroline's future life (despite its
quality limitations) as just as worthy of preservation as anyone else's, the length-
insensitive interpretation of section 1320e-1(c)(1) sees Bill's future life (despite its
limited length) as just as worthy of preservation as anyone else's.
Although the length-insensitive interpretation may seem extreme, it has been
endorsed in the literature, most prominently by the medical ethicist John Hats. Harris
argues that since each person subjectively values her own future life as paramount,
regardless of its length, we should not give priority to someone whose life will be
extended for a long time by treatment over someone who can live, even if treated, for
at most a short period. 116 In Hats' words:
[T]he anti-ageist argument denies the relevance of age or life expectancy
as a criterion absolutely. It argues that even if I know for certain that I
have only a little space to live, that space, however short, may be very
precious to me. Precious, precisely because it is all the time I have left,
113 42 U.S.C. § 1395c (restricting access to Medicare to individuals over sixty-five, disabled
individuals receiving Social Security benefits, and individuals with end-stage renal disease); see also 42
U.S.C. § 1395o (requiring that Medicare Part B beneficiaries be over sixty-five years of age or eligible for
Part A).
114 42 U.S.C. § 1320e-1(c)(1).
.. 42 U.S.C. § 1320e-l(c)(2)(A).
116 John Harris, Does Justice Require That We BeAgeist?, 8 BIOETHICS 74, 74-83 (1994).
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and just as precious to me on that account as all the time you have left is
precious to you, however much those two lifespans differ in length. So
that where we both want, equally strongly, to go on living, then we each
suffer the same injustice when our lives are cut short or are cut further
short.
117
Harris makes an impassioned case for length insensitivity, but accepting his claims
would have striking and counterintuitive implications. Priority-setting methods that
adopt Harris's view would require us to be indifferent between extending someone's
life for five minutes and extending someone else's for fifty years.118
Ignoring differences in the amount of life different patients gain is ethically
dubious in at least two ways. First, it requires a particularly strong version of the claim
that interpersonal comparisons of well-being are impossible. Even if some
interpersonal comparisons are challenging, certain particularly clear ones seem
soluble; it seems reasonable to believe that the Romans lost more when Rome burned
than Nero gained as he fiddled.1 19 The same seems true when we compare five minutes
of life to fifty years. Second, even if someone really could experience just as great a
gain of subjective well-being by gaining five extra minutes as someone else could by
gaining fifty years, fairness-to the extent it diverges from the maximization of
subjective well-being-may still require giving priority to the person who would gain
fifty years. Even if a wealthy but miserly person would gain just as much subjective
well-being from gaining five dollars as a poor person would gain by doubling her
meager income, fairness arguably still requires us to help the poor person first."'
As such, section 1320e-l(c)(2)(A) is better interpreted in a length-sensitive way.
The most natural way of understanding the language permitting Medicare to consider a
"difference in extending life" 12 1 would include not only differences in whether a
treatment extends someone's life, but by how many years that life is extended. The
length-sensitive interpretation, although it considers differences between patients when
determining the potential effectiveness of treatments, regards an additional year of life
for any patient as equally important. Individuals with short life expectancies, unlike
the elderly or the disabled, are not a group elsewhere recognized in antidiscrimination
law.
One potential hybrid between the length sensitive and length insensitive views
would focus on the language in section 1320e-l(c)(2)(A) that permits "comparison of
the difference in the effectiveness of alternative health care treatments in extending an
individual's life due to that individual's age, disability, or terminal illness," and read
the "due to" language to permit consideration of patients' different future lengths of
life when that difference in length of life stems from an interaction between the
patient's illness and the treatment. 122 Per this hybrid view, Medicare could consider the
117 JOHN HARRIS, THE VALUE OF LIFE: AN INTRODUCTION TO MEDICAL ETHICS 90 (Taylor & Francis
e-Library ed., 2001) (footnotes omitted).... David Orentlicher has defended a similar but less extreme view of length insensitivity, asking us to
treat as equal all gains in lifespan that are not de miniis. David Orentlicher, Destructuring Disability:
Rationing of Health Care and Unfair Discrimination Against the Sick, 31 HARv. C.R.-C.L. L. REv. 49, 72-
73 (1996) ("[I]f an organ transplant program excluded persons whose coexisting illnesses prevented them
from gaining more than a few months of benefit from an organ, there should be no problem with the
exclusion. If, however, a program excluded persons who would gain a few years of benefit on the ground
that other persons would gain even more, that kind of exclusion should not be permitted.").
119 AMARTYA SEN, RATIONALITY AND FREEDOM 79 (2004).
120 Cf John Broome, The Ethics of Climate Change, 298 SCI. AM. 96, 99-100 (2008) (differentiating
fairness-based, "prioritarian" arguments from diminishing marginal utility arguments).
121 42 U.S.C. § 1320e-l(c)(2)(A) (2012).
122 id.
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fact that Bill's metastatic prostate cancer limits the amount of additional life that
chemotherapy for that cancer can provide, but could not consider his cancer when
evaluating the benefits of saving Bill from an unrelated illness, such as heart failure.
Although this hybrid view is more plausible than the length-insensitive view, it
construes "due to" overly narrowly. That Bill's metastatic cancer limits how effective
heart disease treatments can be at extending his life by posing a second, independent
threat to his life, rather than by interfering directly with treatment, does not prevent the
cancer from counting as a limitation on heart disease treatment. Additionally, it is
challenging to imagine how comparative effectiveness research could identify these
sorts of fine distinctions in causal structure.
The strongest argument for the length-insensitive interpretation of section 1320e-
l(c)(2)(A) appeals to concerns about surplusage: permitting Medicare to consider the
effects of terminal illness on a treatment's effectiveness in lengthening someone's life
might appear to provide no special protection at all to people with terminal illnesses.
However, it still prohibits one recognized form of priority setting that would
disadvantage people with terminal illnesses, which is the use of thresholds that treat
small amounts of life as irrelevant. 123
Even though the length-sensitive interpretation of section 1320e-l(c)(2)(A)
permits Medicare to give lower priority to treatments for the terminally ill on the basis
that treatment will add fewer years to their lives, it does not permit treating the future
life of a terminally ill individual-no matter how short-as any less important than the
same amount of future life for some other individual. Even though we can prioritize
helping Caroline live for six more years over helping Bill live for six more months,
section 1320e-1(c)(1) prohibits priority setting that would favor helping a healthy
person live for six more months over helping a terminally ill person live six more
months. 124
C. ESSENTIAL HEALTH BENEFITS
The next section of the ACA I discuss applies to any health plan offered through
an Exchange within the ACA. This section sets standards for the "essential health
benefits" that any plan offered through an Exchange must provide.
1. Nondiscrimination in Design
The ACA requires that, in defining a list of essential health benefits, the Secretary
of the Department of Health and Human Services (HHS) "not make coverage
decisions, determine reimbursement rates, establish incentive programs, or design
benefits in ways that discriminate against individuals because of their age, disability,
or expected length of life." 125 The requirement not to discriminate against individuals
because of disability seems to parallel the restrictions placed on PCORI and Medicare,
while the restriction on age discrimination seems parallel to the restrictions placed on
Medicare.
However, the language here is less specific than the language of the Medicare and
PCORI restrictions. While the Medicare restrictions specifically prohibit treating the
extension of life for older, disabled, or terminally ill people as less important, 126 and
the PCORI restrictions limit the use of QALYs because they disadvantage people with
123 Cf Bognar, supra note 99, at 172-73 (discussing examples).
124 42 U.S.C. § 1320e-1(c)(1).
121 Id. § 18022(b)(4)(B).
126 Id. § 1320e-1(c)(1).
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disabilities,"' the essential health benefit provisions refer to the more general concept
of discrimination. 12 Depending on how we understand this concept, it may seriously
limit the use of comparative effectiveness research in defining essential health
benefits.
One interpretation of "discriminate against," which I'll call the "no-weighting"
interpretation, defines discrimination against someone as treating a benefit to her
differently, because of her disability, age, or expected length of life. This interpretation
would treat section 18022(b)(4)(B) as parallel to section 1320e-1, which prohibits
counting an extra year of life for Bill as less valuable because he is disabled, but does
not prohibit counting five years of life for Alice as more valuable than two years of life
for Bill, even when the reason that Bill cannot benefit more is his disability. 121 It
would also allow us to consider the fact that some treatments may cause disability
when deciding what priority to give those treatments.
In contrast, the "benefit-insensitive" interpretation would define discrimination to
include all cases where someone receives a lower priority for a benefit because of her
disability, age, or expected length of life-even where the lower priority stems from
the fact that her disability, age, or expected length of life affects her prospect of benefit
or its expected magnitude.
Many discussions of this language, as well as the related language in the Code of
Federal Regulations, seem-at least on the surface-to embrace the benefit-insensitive
interpretation. For instance, the National Patient Advocate Foundation (NPAF) argues
that
[o]ne's expected length of life is precisely that-expected. The length of
one's life is not certain and essential health benefit decisions should not
make certain that which is merely expected by limiting care because of
its cost. Rather, the decision regarding health benefit availability for
those patients who are not expected to live very long should be left up to
patients, their families and caregivers.130
NPAF's view clearly rejects any priority setting for essential health benefits that gives
a lower priority to treatments that are not expected to produce many years of life
131because their recipients have a very limited life expectancy.. In NPAF's view, health
insurers must ignore the expected medical benefit of interventions when deciding
which interventions to treat as essential.132
Other advocates for expanded access, however, have not advanced such a
sweeping interpretation. For instance, the Orthotic and Prosthetic Alliance argued that
section 18022(b)(4)(B) requires that
as long as a patient is motivated to ambulate and capable of doing so,
prosthetic care is appropriate and the patient's age, disability status, or
expected length of their life cannot be used by health plans to deny
127 Id.
128 Id. § 18022(b)(4).
129 Id. §§ 1320e-1, 18022(b)(4)(B).
130 Rene Cabral-Daniels, Exec. Vice President of Regulatory Affairs, Nat'l Patient Advocate Fund,
Comments at the Department of Health and Human Services' Open Comment Session for Consumer
Advocates on Essential Health Benefits (Oct. 20, 2011), available at http://www.npaf.org/
files/NPAF / 20Comments / 2OProvided% /20to% /20HHS / 20on% /2OEssential / 2OHealth / 20Benefits / 200c
t%2020%20201 l.pdf.
131 id.
132 Id.
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coverage for O&P [orthotic and prosthetic] care ....133
Section 18022(b)(4)(B) only applies to essential benefits; age, disability, and other
factors may be appropriate when setting priorities for nonessential benefits. 134 But,
more importantly, the Orthotic and Prosthetic Alliance's interpretation of section
18022(b)(4)(B) requires the provision of prosthetic care only "as long as a patient is
motivated to ambulate and capable of doing so.",135 They would not prohibit a plan
from refusing to provide a prosthetic to someone who will never walk again even if
she receives the prosthetic, because some other disability prevents her doing so or
because she is certain to die before she recovers enough to walk. 136 In so doing, they
adopt not the benefit-insensitive view, but some sort of threshold view that patients
who can gain sufficient benefit from an intervention (where their capacity to benefit
may depend on their age, disability, or expected length of life), should be entitled to
the intervention, even though their age, disability, or expected length of life limits the
extent of the benefit they can receive. 137
Other contexts in law seem to adopt the no-weighting view, rather than the
benefit-insensitive view. The tort system, for instance, permits judges and juries to
consider the effect of a plaintiff's age, disability, and expected length of life on her
future earning power when calculating the damages she receives, although it does not
permit directly discounting future wages based on the fact that a plaintiff is disabled.131
Another interpretation of discrimination regards discrimination on the basis of
age, disability, or expected length of life as the arbitrary use of these factors. We
might think of this interpretation as mandating a sort of "rational basis test" for
priority-setting decisions that consider age, disability, or expected length of life. Sara
Rosenbaum argues that, rather than prohibiting the use of age, disability, and expected
length of life in setting priorities,
[t]he statute bars discrimination, but not the use of patient characteristics
when such characteristics rest on a reasonable clinical and scientific
evidentiary base. A decision cannot be made "on the basis of age," but a
decision based on clinical factors (age is a recognized clinical factor
when, for example, age is used to determine when to immunize a child
against certain diseases) would not be a decision based on age. 139
HHS appears to have adopted Rosenbaum's suggestion in its own interpretation of the
ACA. 14 HHS noted that "[m]any commenters expressed concern that [the anti-
discrimination provisions] would prevent issuers from employing traditional medical
management techniques, with some requesting that we revise regulatory text to
indicate that evidence-based techniques would not be considered discriminatory.
Others expressed ongoing concern that medical management techniques were often
133 Orthotic & Prosthetic Alliance, supra note 41.
134 42 U.S.C. § 18022(b)(4)(B).
13 Orthotic & Prosthetic Alliance, supra note 41.
136 See id.
13 Cf Orentlicher, supra note 118, at 72-73.
E.g., Loftin v. Wilson, 67 So. 2d 185, 188 (Fla. 1953) (holding that, when assessing damages, "the
jury must consider the person's health, habits, occupation, surroundings and any other elements, which in his
case will be likely to operate for or against his expected length of life, as well as the fact that his earning
power may diminish as his physical and mental strength decline").
139 INST. OF MEDICINE, PERSPECTIVES ON ESSENTIAL HEALTH BENEFITS: WORKSHOP REPORT 87
(2012).
141 Patient Protection and Affordable Care Act; Standards Related to Essential Health Benefits,
Actuarial Value, and Accreditation, 78 Fed. Reg. 12,834, 12,847 (Feb. 25, 2013) (to be codified at 45 C.F.R.
pts. 147, 155, 156).
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used as nuanced mechanisms for discrimination." '14 1 HHS's response to these
commenters is that an insurance plan cannot act "in a manner that discriminates on the
basis of membership in a particular group based on factors such as age, disability, or
expected length of life that are not based on nationally recognized, clinically
appropriate standards of medical practice evidence or not medically indicated and
evidence-based. HHS then gives the example that "a reasonable medical
management technique would be to require preauthorization for coverage of the zoster
(shingles) vaccine in persons under 60 years of age, consistent with the
recommendation of the Advisory Committee on Immunization Practices," and
concludes that "nothing in this section shall be construed to prevent an issuer from
using reasonable medical management techniques." South Dakota has adopted
similar statutory language, specifying that "[i]ssuers may continue to use reasonable
medical management techniques that are evidence based." 144
HHS's and Rosenbaum's attempts to define discrimination as conduct that falls
outside of recognized medical practice are tempting: they delegate to the medical and
scientific professions the task of defining when considerations of age, disability, and
expected length of life are appropriate in healthcare. However, these definitional
decisions are not technical ones. Rather, they are value judgments, which physicians
have no special expertise in making.145 For instance, physicians may decide-and
indeed have decided-that certain transplants are not indicated for patients over a
certain age. But physicians' custom does not necessarily make their choices about
medical priorities just.146 Furthermore, defining discrimination as noncompliance with
custom makes it hard to see how new customs could evolve.
Finally, since the essential health benefits requirements are regulations on private
plans offered through the Exchanges, it is worth considering a different interpretation
of section 18022(b)(4)(B): that the language is actually intended to target efforts by
insurers to exclude people they expect to have long lives. 14 45 CFR § 147.104
provides:
A health insurance issuer and its officials, employees, agents and
representatives ... cannot employ marketing practices or benefit designs
that will have the effect of discouraging the enrollment of individuals
with significant health needs in health insurance coverage or
discriminate based on an individual's race, color, national origin, present
or predicted disability, age, sex, gender identity, sexual orientation,
expected length of life, degree of medical dependency, quality of life, or
other health conditions.1 48
141 Id.
142 Id. (emphasis added).
143 Id.
144 S.D. ADMIN. R. 20:06:56:09 (2013).
141 See Tony Hope et al., "Not Clinically Indicated": Patients' Interests or Resource Allocation?, 306
BRIT. MED. J. 379, 380 (1993); cf. E. Haavi Morreim, Futilitarianism, Exoticare, and CoercedAltruism: The
ADA Meets Its Limits, 25 SETON HALL L. REv. 883, 907 (1995) ("[P]hysicians cannot appeal to medical
science to determine that a patient's life-his very existence-is somehow 'medically contraindicated.' It is
here that controversies should be resolved, not by professional declaration, but by societal negotiation.").
146 Cf Benjamin Eidelson, Comment, Kidney Allocation and the Limits of the Age Discrimination Act,
122 YALE L.J. 1635, 1645 (2013) ("But when age is cast as a proxy for conditions such as heart disease, and
incorporated alongside other paradigmatically medical criteria such as diabetes status, the inference from
years lived to years left is attenuated and 'medicalized' in a way that may invite greater deference.").
141 See Thomas L. Greaney, The Affordable Care Act and Competition Policy: Antidote or Placebo?,
89 OR. L. REV. 811, 827 (2011).
148 45 C.F.R. § 147.104(e) (2013).
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The placement of this language suggests that it aims to prohibit insurers from cherry-
picking healthy patients or violating other provisions of antidiscrimination law, 149 not
that it aims to prohibit insurers from considering the fact that a treatment may result in
disability or may fail to extend life as much as an alternative.
2. Nondiscrimination in Provision
The section on essential health benefits also contains language that prevents the
denial of benefits classified as essential to individuals based on certain factors. 150 It
requires that the Secretary:
ensure that health benefits established as essential not be subject to
denial to individuals against their wishes on the basis of the individuals'
age or expected length of life or of the individuals' present or predicted
disability, degree of medical dependency, or quality of life. 151
Similar language also exists in a section on Medicare Advantage demonstration
projects, which provides that:
The criteria employed under the demonstration program under this
section to evaluate outcomes and determine best practice guidelines and
incentives shall not be used as a basis for the denial of medicare benefits
under the demonstration program to patients against their wishes (or if
the patient is incompetent, against the wishes of the patient's surrogate)
on the basis of the patient's age or expected length of life or of the
patient's present or predicted disability, degree of medical dependency,
or quality of life. 152
Section 18022(b)(4)(D) pertains to the provision of benefits antecedently
'established as essential," and thus operates in conjunction with section
18022(b)(4)(B), which proscribes discrimination in the determination of which
benefits are essential. 153 However, even if section 18022(b)(4)(B)'s prohibition on
discrimination is understood expansively, section 18022(b)(4)(D) will still be relevant.
A health benefit defined as essential using nondiscriminatory criteria might still in
practice be denied to individuals in a way that violates section 18022(b)(4)(D). And
the Medicare Advantage provisions are particularly significant, since Medicare is not
otherwise prohibited from considering the effect of age, disability, or terminal illness
on treatment effectiveness. 154
Section 18022(b)(4)(D) and similar statutes may require the provision, at a
patient's request, of treatments even in cases where the treatment provides minimal
benefit or could be harmful to the patient. For instance, it might interfere with
Oregon's Medicaid program's efforts to restrict access to cancer treatment "with an
149 See Greaney, supra note 147, at 827.
"' 42 U.S.C. § 18022(b)(4)(D) (2012).
151 id.
152 42 U.S.C. § 1395cc-3.
151 Id. § 18022(b)(4)(B).
154 See, e.g., Michael J. DeBoer, Medicare Coverage Policy and Decision Making, Preventive Services,
and Comparative Effectiveness Research Before and After the Affordable Care Act, 7 J. HEALTH &
BIOMEDICAL L. 493, 563 (2012) (quoting 42 U.S.C. § 1320e-1(c)(1) (2012)) ("The ACA does, however,
prohibit the Secretary from using evidence or findings from comparative clinical effectiveness research
under section 1181 of the Social Security Act in determining Medicare coverage, reimbursement, or
incentive programs 'in a manner that treats extending the life of an elderly, disabled, or terminally ill
individual as of lower value than extending the life of an individual who is younger, nondisabled, or not
terminally ill.'").
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intent to prolong survival" on the basis of quality of life:
Treatment with intent to prolong survival is not a covered service for
patients who have progressive metastatic cancer with
1) severe co-morbidities unrelated to the cancer that result in significant
impairment in two or more major organ systems which would affect
efficacy and/or toxicity of therapy; OR
2) a continued decline in spite of best available therapy with a non
reversible Karnofsky Performance Status or Palliative Performance score
of <50% with ECOG performance status of 3 or higher which are not
due to a pre-existing disability.155
This Oregon language has been challenged by a coalition of cancer advocacy groups,
who allege that it constitutes a violation of section 18022(b)(4)(D). 156 However,
although section 18022(b)(4)(D) is broader than section 18022(b)(4)(B), since it
prohibits decisions "on the basis of' certain factors rather than merely prohibiting
discrimination on the basis of those factors, 157 Oregon might argue that its policy is
justified on the basis of medical inappropriateness, or on the basis of a physician's
duty not to harm, rather than on the basis of bare life expectancy.
To settle the dispute, agencies and courts would have to offer their own
interpretations of the "on the basis of' language. The construction of similar text in
other statutes, such as the Age Discrimination in Employment Act, the Age
Discrimination Act, and the Americans with Disabilities Act, has been much
debated. 158 Some cases have suggested that "on the basis of' requires proof of
proximate causation, 159 while others note that consideration of age may be appropriate
where consideration of other factors is categorically prohibited. 16 There is also active
debate over whether subtle differences in language between statutes affect the
applicability of case law interpreting similar statutes. 161
... Health Evidence Review Commission: New Cancer Treatment Guideline, OREGON.GOV,
http://www.oregon.gov/oha/herc/Pages/New-Cancer-Treatment-Guideline.aspx (last visited Apr. 2, 2015).
116 See, e.g., Letter from The Leukemia & Lymphoma Soc'y et al., to Diane Gerrits, Dir. of the Div. of
State Demonstrations & Waivers, Ctrs. for Medicare & Medicaid Sews. (Sept. 27, 2013) (on file with
author), available at
http://community.lls.org/blog/l/entry-282-oregon-cms-advocate-letter/.
117 Compare 42 U.S.C. § 18022(b)(4)(D) (2012), with § 18022(b)(4)(B).
... See Univ. of Tex. Sw. Med. Ctr. v. Nassar, 133 S. Ct. 2517, 2531 (2013) (discussing the Supreme
Court's disparate interpretations of "discrimination" in the context of the Americans with Disabilities Act
and the Age Discrimination in Employment Act); Gross v. FBL Fin. Sews., 557 U.S. 167, 176 (2009)
(analyzing the plain meaning of the phrase "because of' in the Age Discrimination in Employment Act); see
also Ky. Ret. Sys. v. EEOC, 554 U.S. 135, 142 (2008) (considering legislative intent when ruling on a
disparate-treatment claim under the Age Discrimination in Employment Act); Hazen Paper Co. v. Biggins,
507 U.S. 604, 608 (1993) ("The Courts of Appeals repeatedly have faced the question whether an employer
violates the ADEA by acting on the basis of a factor, such as an employee's pension status or seniority, that
is empirically correlated with age.").
"9 E.g., Petock v. Thomas Jefferson Univ., 630 F. Supp. 187, 189 (E.D. Pa. 1986) (citing Lewis v.
Univ. of Pittsburgh, 725 F.2d 910, 914 (3d Cir. 1983)).
160 Smith v. City of Jackson, 544 U.S. 228, 240 (2005) ("[A]ge, unlike race or other classifications
protected by Title VII, not uncommonly has relevance to an individual's capacity to engage in certain types
of employment.").
161 See Serwatka v. Rockwell Automation, Inc., 591 F.3d 957, 961 n.1 (7th Cir. 2010) (explaining that
older "because of' language in Americans with Disabilities Act entailed a but-for causation requirement, but
noting that newer "on the basis of' language might have different implications); Quillen v. Touchstone Med.
Imaging L.L.C., 15 F. Supp. 3d 774, 780 n.10 (M.D. Tenn. Apr. 18, 2014) (collecting cases interpreting the
"on the basis of' language); Southerland v. Dep't of Def., 2011 M.S.P.B. 92, 38 (2011), affd as modified,
119 M.S.P.B. 46 (2013) (holding "that the phrase 'on the basis of' in the [ADA Amendments Act of 2008]
means the same thing as 'because of' in the ADA and, therefore, requires application of the same 'but for'
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Minnesota's state statutory language on essential health benefits similarly states
that:
,'Clinically effective" means that the use of a particular health
technology or service improves or prevents a decline in patient clinical
status, as measured by medical condition, survival rates, and other
variables, and that the use of the particular technology or service
demonstrates a clinical or outcome advantage over alternative
technologies or services. This definition shall not be used to exclude or
deny technology or treatment necessary to preserve life on the basis of
an individual's age or expected length of life or of the individual's
present or predicted disability, degree of medical dependency, or quality
of life. 162
The definition of "cost-effective" contains an identical proviso. 16 3 However, the
Minnesota language differs subtly from the ACA's essential health benefits language:
rather than applying to all health benefits, the Minnesota statute only prohibits the use
of clinical effectiveness or cost-effectiveness data to deny access to treatment where
the treatments in question are "necessary to preserve life." 164
Ultimately, assessing how to understand the antidiscrimination requirements on
the provision of essential health benefits may depend on the details of the benefits in
question. If the benefit is a low cost treatment that minimizes pain and suffering and
whose effectiveness does not differ drastically between patients, then it could make
sense not to deny a benefit on the basis of differences in medical benefit that stem
from age, disability, or short life expectancy. Providing such a benefit, regardless of
whether its effectiveness is low because of the patient's comorbidities or advanced
age, might have the expressive significance of recognizing the patient's continued
membership in the community, and the importance of responding to her preferences
about healthcare. 165 Such considerations might outweigh concerns about low cost-
effectiveness.
In contrast, if some benefits regarded as essential are high cost, last chance
treatments whose benefit is almost nonexistent for some already very ill patients,
preventing the consideration of age, disability, or prognosis seems much harder to
defend. Requiring the provision of such treatments would require the healthcare
system to incur high costs and could place physicians in the position of providing
medical care they professionally regard as harmful.
Ultimately, the most challenging cases involve high cost treatments that do
prevent pain and suffering. In such cases, a pure cost-effectiveness approach would
consider the differing extents to which the treatment prevents pain and suffering in
different patients, while an approach that ignores prognosis would treat patients
identically. Where the treatment to be provided will not be provided to everyone,
treating patients identically has the expressive virtue of equal regard for all, but the
disadvantage of ignoring differences in patients' needs and capacity to benefit.
test discussed in Gross"); Brian S. Clarke, Grossly Restricted Pleading: Twombly/Iqbal, Gross, and
Cannibalistic Facts in Compound Employment Discrimination Claims, 2010 UTAH L. REv. 1101, 1125
n.164 (2010) (asserting that "the terms 'because of' and 'on the basis of' are essentially identical").
162 MINN. STAT. ANN. § 62U.01 subd. 3 (West 2013).
163 Id. § 62U.01 subd. 5.
164 id.
16' For a discussion of the expressive significance of legal requirements, see generally Elizabeth S.
Anderson & Richard H. Pildes, Expressive Theories of Law: A General Restatement, 148 U. PA. L. REV.
1503 (2000).
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3. Fairness to Diverse Segments of the Population
The essential health benefits section contains language that requires a much
broader shift away from thinking in traditional cost-effectiveness terms than any of the
other text does. This section specifies that essential health benefit determinations must
"take into account the health care needs of diverse segments of the population,
including women, children, persons with disabilities, and other groups. ,166 This section
would prohibit the selection of essential health benefits simply by beginning with the
most cost-effective interventions and proceeding down the list until some cutoff point
was reached. 167 Rather, choices about essential health benefits should be fair to
different relevant subgroups within the population. For example, even if the greatest
net benefit could be obtained by providing services that reach only urban populations,
appropriately considering the needs of subgroups requires deviating from the strict
pursuit of total benefit.
Among the most major challenges section 18022(b)(4)(C) poses is the question of
which "diverse segments" are relevant. While the statute specifies that women,
children, and persons with disabilities must be considered when setting priorities, it
leaves open which other categories might be relevant. In its Final Rule on Essential
Health Benefits, codified at 45 C.F.R. § 156.125, HHS stated that an issuer of
insurance fails to provide essential health benefits if "its benefit design, or the
implementation of its benefit design, discriminates based on an individual's age,
expected length of life, present or predicted disability, degree of medical dependency,
quality of life, or other health conditions,"' 169 or discriminates "on the basis of race,
color, national origin, disability, age, sex, gender identity or sexual orientation.17
The most likely provisions to produce debate are those familiar to
antidiscrimination law but also clearly relevant to medical practice, such as age and
disability, as well as those unfamiliar to antidiscrimination law, such as length and
quality of life, and degree of medical dependency. Some of the factors discussed in
section 156.125, such as race, color, national origin, gender, gender identity, and
sexual orientation, 171 are somewhat less likely to produce debate. However, given that
some vulnerabilities-such as sickle cell trait and prostate cancer-are directly
connected to these factors, and many others are correlated with them, these
antidiscrimination rules may play a role here as well.
That the Final Rule employs the concept of discrimination based on a factor,
rather than categorically stating that certain factors can never be considered, places the
question of which forms of priority setting constitute discrimination front and
center. 172 Perhaps the most important threshold questions here will involve the line
between "reasonable medical management techniques," which the regulation regards
as nondiscriminatory, and discriminatory designs. There has been recent debate, but
not yet litigation, regarding what constitutes a reasonable medical management
166 42 U.S.C. § 18022(b)(4)(C) (2012).
167 Id. § 18022(b)(4)(A). This was more or less the approach that Oregon followed in initial versions of
its Medicaid plan. See La Puma, supra note 67, at 434 ("The legislature has decided how far down the list to
go ... and how much more to approve the health care of Oregon's medically indigent.").
168 See id. § 18022(b)(4)(C) (using the phrase "other groups").
169 45 C.F.R. § 156.125(a) (2014).
171 Id. § 156.200(e); see also id. § 156.125(b) ("An issuer providing EHB must comply with the
requirements of § 156.200(e) of this subchapter.").
171 See id. §§ 156.125(b), 156.200(e).
172 See generally Jessica L. Roberts, 'Healthism': A Critique of the Antidiscrimination Approach to
Health Insurance and Health-Care Reform, 2012 U. ILL. L. REv. 1159, 1187-89 (reviewing and critiquing
antidiscrimination provisions in the ACA).
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technique versus a discriminatory design. Sara Rosenbaum notes that:
the rules provide no specific illustrations of what would be
discriminatory, nor are illustrative examples provided as to what would
be an appropriate and reasonable medical management technique .... It
is unclear what types of conduct HHS believes would cross the line, nor
do the rules indicate the process that will be used to monitor
discrimination. The Preamble . . . however, clarifies that HHS expects
that states, as the primary enforcement arm of [essential health benefit]
requirements as an insurance market regulatory standard, will take the
lead in enforcing this provision (as well as other provisions of the Act
related to market reforms). An unknown issue is how states are
approaching the problem of insurance discrimination, how
discrimination is defined, or the procedures that will be used to identify
discrimination (plan document reviews; actual review of coverage
decisions and claims payment). Presumably individuals may appeal
coverage denials on the basis of the discrimination prohibition, which
offers one mechanism for reviewing plan conduct. 173
This lack of clarity has prompted worries from providers. 174 Concerns about whether
benefit designs are discriminatory fall into three broad categories. One set of concerns
focuses on whether designs treat individual participants differently based on health
condition; 175 another set focuses on whether designs systematically disadvantage
individuals (e.g., all individuals with diabetes or all organ transplant candidates) on the
basis of their membership in an illness-based class.176 A third set of questions concerns
insurance designs that systematically disadvantage individuals who are members of
non-illness-based classes-for instance, women or children. 177
a. Discrimination Against Ill Individuals
If 45 C.F.R. § 156.125(a) is read to require that individuals not receive differential
treatment from insurers based on their health conditions, the regulation's impact on
efforts to set priorities and promote cost-effectiveness might be substantial. The
National Association of Insurance Commissioners notes that "[t]his provision might be
interpreted as preempting state laws that permit medical necessity limitations on
coverage or promote the cost-effective delivery of benefits, except to the extent that
they constitute the kind of 'reasonable medical management techniques' permitted by
173 Sara Rosenbaum, Update: Essential Health Benefits Final Rule, HEALTHREFORMGPS (Mar. 13,
2013), http://healthreformgps.org/resources/update-essential-health-benefits-final-rule-2/.
174 KATIE KEITH ET AL., NONDISCRIMINATION UNDER THE AFFORDABLE CARE ACT 12 (2013),
available at http://ssrn.com/abstract-2362942 (reporting that "one insurer questioned whether the use of
age-based clinical criteria (such as preventive services recommended only for children or adults of a certain
age) would be considered 'reasonable medical management techniques' (which is allowed under federal
regulations) or discriminatory based on age (which is prohibited)").
171 See id. at 7 ("[I]nsurers in most states can deny or limit coverage based on health status.") (citing
KAISER FAMILY FOUND., HEALTH INSURANCE MARKET REFORMS: GUARANTEED ISSUE 1 (2012), available
at http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8327.pdf).
176 Id. (citing Dana P. Goldman et al., Benefit Design and Specialty Drug Use, 25 HEALTH AFF. 1319
(2006); KATE FITCH & BRUCE PYENSON, BENEFIT DESIGNS FOR HIGH COST MEDICAL CONDITIONS (2011))
("[C]onsumers may face high cost-sharing for chronic diseases.").
177 Id. (citing DANIELLE GARRETT ET AL., TURNING TO FAIRNESS: INSURANCE DISCRIMINATION
AGAINST WOMEN TODAY AND THE AFFORDABLE CARE ACT 7 (2012), available at http://www.nwlc.org/
sites/default/files/pdfs/nwlc 2012 turningtofaimess report.pdf) ("Women continue to be charged more for
coverage.").
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HHS under 45 CFR § 156.125(c)." '178 For example, a recent presentation asks whether
a variety of benefit designs might constitute discrimination, such as formularies that
exclude drugs and devices subject to registries; restrictions of patients on many
prescriptions to a single pharmacy provider; value-based designs that eliminate
copayments and coinsurance for generic drugs while maintaining them for branded
drugs; and "fail first" policies where patients must first try the preferred drug before
receiving alternatives. 179 Many of these designs have the potential to maintain a high
overall level of medical care while containing costs, but could disadvantage specific
individuals who suffer adverse events from the interventions that are overall most cost-
effective. For example, formularies may serve the interests of the patient population as
a whole while disadvantaging specific patients: a recent commentary alleges that
formularies "subordinate the heterogeneity of patient need and response to the primacy
of cost control."'18
While policies catering to each individual's unique medical situation might be
desirable in an ideal world, some disadvantage to individuals with unusual or costly
medical needs seems inevitable and, while disadvantaging, not objectionably
discriminatory. Every population-wide rule, from the age of majority to the speed
limit, invariably has negative impacts on certain individuals. While systematic
disadvantage to a protected class would warrant remedial action, the mere fact that a
rule has winners and losers does not. Permitting individuals who lose out under a
systematically applied, evidence-based guideline due to their individual medical
situation, rather than any membership in a protected class, to prevail on complaints of
discrimination would make the application of guidelines impossible and, more
importantly, would stretch the meaning of discrimination beyond recognition. While a
few individuals have challenged regulations as arbitrary under the Equal Protection
Clause (in what are called "class of one" cases) and prevailed,181 such claims must
involve intentional discrimination-or, in some courts' view, animus-motivated
discrimination' 2--between individuals who are strictly identically situated: the
uniqueness of an individual's situation is not enough to support a "class of one"
claim.183 As the Supreme Court recently noted, antidiscrimination law cannot stipulate
178 ACA Impact on State Regulatory Authority: Qualified Health Plans, NAT'L INST. INS.
COMMISSIONERS, http://web.archive.org/web/20130502150248/http://www.naic.org/documents/committees
b exchanges hcr reg alt wg 130325 analysis hix.pdf (last visited Feb. 17, 2015).
179 DONNA A. BOSWELL, ACCESS To CARE UNDER HEALTH REFORM: How WILL PATIENTS OBTAIN
INNOVATIVE THERAPIES 20 (2013), available at http://www.womeningovernment.org/files/
DonnaBoswell.pdf.
"0 Gary Puckrein, The National Healthcare Quality Report and Essential Health Benefits: Opportunity
Squandered, HUFFINGTON POST (May 29, 2013), http://www.huffingtonpost.com/gary-puckrein/the-
national-healthcare-tb 3352778.html; Letter from the AIDS Action Comm. of Mass. et al., to Kathleen
Sebelius, Sec'y, Health & Human Sews. (Oct. 2, 2012) (on file with the AIDS Institute), available at
http://www.theaidsinstitute.org/sites/default/files/attachments/Sebelius/ 020EHB / 201etter/ 2oct/o2020l2.p
df.
'g' See, e.g., Vill. of Willowbrook v. Olech, 528 U.S. 562, 563 (2000) (holding that an individual's
allegation that a regulation's application to her was "irrational and wholly arbitrary" was sufficient to state a
claim for relief under the Equal Protection Clause (internal quotation marks omitted)).
182 See Racine Charter One, Inc. v. Racine Unified Sch. Dist., 424 F.3d 677, 683-84 (7th Cir. 2005)
(collecting cases); see also Benjamin L. Schuster, Fighting Disparate Treatment: Using the 'Class of One'
Equal Protection Doctrine in Eminent Domain Settlement Negotiations, 45 REAL PROP. TR. & EST. L.J. 369,
392 (2010) (noting that some courts require animus in "class of one" cases).
183 E.g., Level Dev. Corp. v. Pisani, No. 3: 10CV820 (MRK), 2012 WL 2397360, at *4 (D. Conn. June
25, 2012) ("Instead of pointing to the similarities between Level and its proposed comparators, Level's brief
on this issue lingers instead on the ways in which Level's quarry is 'atypical,' 'peculiar,' and 'sui generis.'..
• Yet without a similarly situated comparator-much less any evidence in the record of intentional
discrimination by Defendants-Level's class-of-one equal protection claim must fail as a matter of law.").
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how individuals should be treated by decision makers exercising discretion:
Suppose, for example, that a traffic officer is stationed on a busy
highway where people often drive above the speed limit, and there is no
basis upon which to distinguish them. If the officer gives only one of
those people a ticket, it may be good English to say that the officer has
created a class of people that did not get speeding tickets, and a 'class of
one' that did. But assuming that it is in the nature of the particular
government activity that not all speeders can be stopped and ticketed,
complaining that one has been singled out for no reason does not invoke
the fear of improper government classification. Such a complaint, rather,
challenges the legitimacy of the underlying action itself-the decision to
ticket speeders under such circumstances. Of course, an allegation that
speeding tickets are given out on the basis of race or sex would state an
equal protection claim, because such discriminatory classifications
implicate basic equal protection concerns. But allowing an equal
protection claim on the ground that a ticket was given to one person and
not others, even if for no discernible or articulable reason, would be
incompatible with the discretion inherent in the challenged action. It is
no proper challenge to what in its nature is a subjective, individualized
decision that it was subjective and individualized. 18 4
Like the police officer's decision, an insurer's decision to provide treatments for one
patient but not another should not be subject to equal protection review without an
allegation of inappropriate classification. 185 Furthermore, in contexts like insurance
where limited resources are being deployed, allowing "class of one" claims would
invariably impose losses on others, frequently those greater in number but less
powerful. For instance, allowing a "class of one" plaintiff to compel an insurer to
provide her with brand name treatments that best cater to her unique physiology will
mean that other plan participants pay higher prices for generic drugs due to a loss of
economies of scale. 186 The ACA should not encourage this extreme form of interest
group policymaking. 18 7 For this reason, I agree with the Employee Retirement Income
Security Act (ERISA) Industry Committee's call for HHS to make clear that insurers
may employ a population-wide guideline rather than needing to provide specific,
tailored benefits for the needs of particular individuals.188
184 Engquistv. Or. Dep't of Agric., 553 U.S. 591, 603-04 (2008); see also Las Lomas Land Co. v. City
of L.A., 177 Cal. App. 4th 837, 860 (Cal. Ct. App. 2009) (rejecting a "class of one" claim where the city had
numerous legitimate reasons for choosing not to expand its boundaries).
... Cf Endsley v. Luna, No. CV 06-04100 DSF (SS), 2009 WL 3806266, at *3 (C.D. Cal. Nov. 12,
2009), affd, 473 F. App'x 750 (9th Cir. 2012) (noting that "[a] state hospital for the mentally ill presents
exactly the kind of situation identified by the Supreme Court requiring 'discretionary decisiormaking based
on a vast array of subjective, individualized assessments,"' and therefore barring patient's class of one
claim).
186 Cf E. Haavi Morreim, Futilitarianism, Exotcare, and Coerced Altruism: The ADA Meets Its Limits,
25 SETON HALL L. REv. 883, 917 (1995) ("If more of the pharmaceutical budget is spent on high-cost life-
saving drugs, less of it will be available to offer a broad variety of choices for more common maladies like
hypertension, arthritis, and asthma.").
117 On the dangers of interest group policymaking, see generally MANCUR OLSON JR., THE LOGIC OF
COLLECTIvE ACTION (1965).
... Public Comment Letter from the ERISA Indus. Comm., to the Internal Revenue Serv. (Sept. 7,
2010) (on file with the Federal eRulemaking Portal), available at http://www.eric.org/forms/uploadFiles/
2390800000106.filename.ERIC Comments Preventive Services Reg090710.pdf ("The Departments also
should make clear that a plan may limit its coverage to the preventive services that are appropriate for the
general population defined by the recommendations and guidelines (for example, men aged 35 and older):
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b. Discrimination Against Medically Defined Classes
Rules subjecting all patients with a given health condition to a given type of
treatment come closer to violating existing antidiscrimination provisions. However, as
a threshold matter, the Equal Protection Clause does not treat classifications based on
health needs or illness as protected classes. Absent additional statutory law (such as
the ACA), legislation disadvantaging individuals on the basis of health classifications
would be subject to rational basis review.'" The Supreme Court has struck down
legislation disadvantaging mentally ill individuals according to disease classifications,
but on the basis that the legislation was prejudiced rather than on the basis that the
classifications were protected. 190 In doing so, the Court noted that
if the large and amorphous class of the mentally retarded were deemed
quasi-suspect for the reasons given by the Court of Appeals, it would be
difficult to find a principled way to distinguish a variety of other groups
who have perhaps immutable disabilities setting them off from others,
who cannot themselves mandate the desired legislative responses, and
who can claim some degree of prejudice from at least part of the public
at large. One need mention in this respect only the aging, the disabled,
the mentally ill, and the infirm. We are reluctant to set out on that
course, and we decline to do so. 191
Courts have refused, for this reason, to strike down medical coverage rules as equal
protection violations. 192
Although the Equal Protection Clause applies mere rational basis review to
legislation disadvantaging individuals along illness-based lines, statutory law (such as
the ACA) can justify subjecting such legislation to more searching review by defining
legislation that imposes disadvantage along illness-based classifications as violations
of the statute. However, courts have also been hesitant to interpret statutory
antidiscrimination language in the ADA and the Rehabilitation Act, which prohibit
discrimination against people with disabilities, to prohibit benefit designs that provide
different levels of coverage for patients with different conditions. In Bernard B. v.
Blue Cross and Blue Shield of Greater New York, the Southern District of New York
rejected plaintiffs' claim that the Rehabilitation Act barred an insurer from excluding
mental health benefits from an insurance plan, stating that:
The logical consequence of plaintiffs' contention would be to mandate
that, if any medical benefits were provided, there could be no benefits
excluded regardless of the costs of providing the treatment in question or
the preferences of the insured group. We do not believe that Congress
intended to prohibit all medical insurance which was less than total in its
coverage, for the necessary consequence of such a ruling would be either
the plan is not required to cover more frequent screenings or other additional services for specific
individuals within that population who might be at higher risk for a particular condition (for example, a man
with a family history of cardiovascular disease).").
"9 City of Cleburne v. Cleburne Living Ctr., 473 U.S. 432 (1985) (holding that a distinction between
the mentally ill and others must be rationally related to a legitimate government purpose).
'90 See City of Cleburne, 473 U.S. at 450.
191 Id. at 445-46.
192 E.g., Fournier v. Sebelius, 718 F.3d 1110, 1123-24 (9th Cir. 2013), cert. denied sub nom. Berg v.
Sebelius, 134 S. Ct. 1501 (2014); Lopez v. Corr. Med. Servs., No. 04-2155 (NLH), 2009 WL 1883915, at
*10 (D.N.J. June 30, 2009), affd, 499 F. App'x 142 (3d Cir. 2012) ("The most that Lopez has alleged is that
those inmates with risk factors other than HIV may not have been screened as promptly as those with HIV.
There is no evidence to suggest that Defendants intentionally, and without a rational basis, singled out Lopez
and refused to screen or treat just him.").
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to end all medical insurance or to require drastic reduction in the amount
of allowable benefits for those risks of primary concern to the covered
employees. We do not believe that the Rehabilitation Act mandates that
the decision between, for example, dental or psychiatric coverage,
assuming cost considerations preclude both at a reasonable benefit level,
is one which cannot be left to the employer, his employees and the
insurer."'
Similarly, in Alexander v. Choate, the Supreme Court refused to interpret the
Rehabilitation Act to strike down a reduction in covered hospital days within
Tennessee's Medicaid program, noting that:
... Medicaid programs do not guarantee that each recipient will receive
that level of health care precisely tailored to his or her particular needs.
Instead, the benefit provided through Medicaid is a particular package of
health care services, such as 14 days of inpatient coverage. That package
of services has the general aim of assuring that individuals will receive
necessary medical care, but the benefit provided remains the individual
services offered-not 'adequate health care.' ... To conclude otherwise
would be to find that the Rehabilitation Act requires States to view
certain illnesses, i.e., those particularly affecting the handicapped, as
more important than others and more worthy of cure through
government subsidization. Nothing in the legislative history of the Act
supports such a conclusion. Section 504 seeks to assure evenhanded
treatment and the opportunity for handicapped individuals to participate
in and benefit from programs receiving federal assistance. The Act does
not, however, guarantee the handicapped equal results from the
provision of state Medicaid, even assuming some measure of equality of
health could be constructed. 19 4
The Alexander Court went on to note that interpreting the Rehabilitation Act to
produce maximal advantage for patients with specific illnesses would be both
unworkable and unfair to other groups:
[T]o require that the sort of broad-based distributive decision at issue in
this case always be made in the way most favorable, or least
disadvantageous, to the handicapped, even when the same benefit is
meaningfully and equally offered to them, would be to impose a
virtually unworkable requirement on state Medicaid administrators.
Before taking any across-the-board action affecting Medicaid recipients,
an analysis of the effect of the proposed change on the handicapped
would have to be prepared. Presumably, that analysis would have to be
further broken down by class of handicap-the change at issue here, for
example, might be significantly less harmful to the blind, who use
inpatient services only minimally, than to other subclasses of
handicapped Medicaid recipients; the State would then have to balance
the harms and benefits to various groups to determine, on balance, the
extent to which the action disparately impacts the handicapped. In
addition, respondents offer no reason that similar treatment would not
have to be accorded other groups protected by statute or regulation from
193 Bernard v. Blue Cross & Blue Shield of Greater N.Y., 528 F. Supp. 125, 132-33 (S.D.N.Y. 1981),
affd, 679 F.2d 7 (2d Cir. 1982).194 Alexander v. Choate, 469 U.S. 287, 303-04 (1985) (citations omitted).
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disparate-impact discrimination. 195
Lower courts have interpreted Alexander to foreclose similar attempts to require
insurers to provide coverage for individuals' or groups' specific needs. 19 6 However,
other courts have been more willing to apply antidiscrimination law to healthcare
decisions that disadvantage patients with specific diseases. The Eighth Circuit
compelled an insurer to provide coverage in Henderson v. Bodine Aluminum, Inc.,
holding that "if the evidence shows that a given treatment is non-experimental that
is, if it is widespread, safe, and a significant improvement on traditional therapies-
and the plan provides the treatment for other conditions directly comparable to the one
at issue, the denial of that treatment arguably violates the ADA." 197 And the Ninth
Circuit held in Rodde v. Bonta that a locality could not close a hospital that treats
patients with disabilities while leaving other hospitals open. 198
There have also been debates about priority setting at the level of physicians and
hospitals. Several courts have refused to interpret the ADA and the Rehabilitation
Act's antidiscrimination provisions to require hospitals to treat patients with specific
illnesses, such as infants and adults with disabilities'" and patients with HIV,2 00 or to
provide patients with disabilities with legal remedies for nontreatment or negligent
treatment related to their disabling illness.] 1 However, other courts have been more
willing to step in, for instance, to indicate that the ADA requires the treatment of an
anencephalic infant, and would also require a hospital to ignore the fact that a patient
202is likely to die of other causes when deciding whom to treat, or provide recourse
'9' Id. at 308.
196 Cohon ex rel. Bass v. N.M. Dep't of Health, 646 F.3d 717, 726-27 (10th Cir. 2011) (rejecting claim
that Medicaid benefits sufficient "to serve the interests of the Medicaid population as a whole" but
insufficient for plaintiff's needs constituted a Rehabilitation Act violation); Doe v. Mut. of Omaha Ins. Co.,
179 F.3d 557, 560 (7th Cir. 1999), cert. denied, 528 U.S. 1106 (2000) (rejecting claim that caps on treatment
for AIDS-related illnesses violate the ADA); Lenox v. Healthwise of Ky., Ltd., 149 F.3d 453, 457 (6th Cir.
1998) (rejecting claim that a "plan violates the ADA because it covers some types of transplants, but not
heart transplants"); Modderno v. King, 871 F. Supp. 40, 43 (D.D.C. 1994), affd, 82 F.3d 1059 (D.C. Cir.
1996), cert. denied, 519 U.S. 1094 (1997) (rejecting claim that differences in benefits violate the
Rehabilitation Act).
'9' Henderson v. Bodine Aluminum, Inc., 70 F.3d 958, 960 (8th Cir. 1995).
198 Rodde v. Bonta, 357 F.3d 988, 997 (9th Cir. 2004); see also Doe, 179 F.3d at 565 (Evans, J.,
dissenting).
'99 Bowen v. Am. Hosp. Ass'n, 476 U.S. 610, 647 (1986) (Stevens, J., plurality opinion) ("Section 504
does not authorize the Secretary to give unsolicited advice either to parents, to hospitals, or to state officials
who are faced with difficult treatment decisions concerning handicapped children."); Schiavo ex rel.
Schindler v. Schiavo, 403 F.3d 1289, 1294 (1 1th Cir. 2005), reh 1g denied en banc, 404 F.3d 1270 (1 1th Cir.
2005); reh 1g denied, 404 F.3d 1282 (11th Cir. 2005); stay denied, 544 U.S. 957 (2005) ("The Rehabilitation
Act, like the ADA, was never intended to apply to decisions involving the termination of life support or
medical treatment"); United States v. Univ. Hosp., State Univ. of N.Y. at Stony Brook, 729 F.2d 144, 157
(2d Cir. 1984) (rejecting the suggestion that a medical judgment not to treat a newborn with a disability
constituted discrimination under the ADA, in part because antidiscrimination principles are inappropriate
when applied to medical judgments); see also Wagner ex rel. Wagner v. Fair Acres Geriatric Ctr., 49 F.3d
1002, 1012 (3d Cir. 1995) (noting that Bowen and University Hospital refused to apply the ADA's
antidiscrimination provisions to "medical treatment cases involving handicapped infants which necessitate
complex assessments of the medical needs, benefits and risks of providing invasive medical care").
200 Lesley v. Chie, 81 F. Supp. 2d 217, 224 (D. Mass. 2000), afJd, 250 F.3d 47 (1st Cir. 2001) (holding
that the Rehabilitation Act "is not meant to apply to medical treatment decisions").
20 Burger v. Bloomberg, 418 F.3d 882, 883 (8th Cir. 2005) ("[A] lawsuit under the Rehab[ilitation]
Act or the Americans with Disabilities Act (ADA) cannot be based on medical treatment decisions.");
Fitzgerald v. Corr. Corp. of Am., 403 F.3d 1134, 1144 (10th Cir. 2005) (stating that "neither the ADA nor
the Rehabilitation Act provide remedies for alleged medical negligence," and collecting cases).
202 In re Baby K, 832 F. Supp. 1022, 1028 (E.D. Va. 1993), affd, 16 F.3d 590 (4th Cir. 1994)
(suggesting that "an AIDS patient seeking ear surgery is 'otherwise qualified' to receive treatment despite
poor long term prospects of living"); see also Bowen, 476 U.S. at 656-57 (White, J., dissenting) ("That some
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under the Rehabilitation Act for medical judgments that are capricious or reflect
stereotypes about individuals with certain medical conditions. 3
In a 2011 law review article, Wendy Hensel and Leslie Wolf argue that courts
should be willing to critically review meso-level and macro-level policies set by
governments and insurers to consider whether these policies are responsive to the
needs of particular individuals. 2°4 The authors maintain that courts should not apply
federal antidiscrimination law (as opposed to state tort and malpractice law) to micro-
level, individualized priority-setting decisions, such as physicians' judgments as to
how specific patients should be treated.2 5 In support of this claim, Hensel and Wolf
point to an unpublished Department of Justice opinion suggesting that physicians
would violate the ADA by categorically excluding a patient with Down syndrome
from access to organ transplantation rather than engaging in "an individualized
,206assessment of her actual abilities." Some have similarly argued that organ
transplantation eligibility rules should be revised to require individual assessment of
medical condition by a physician, 2°7 and California and New Jersey have in fact
adopted laws to this effect.2 08The suggestion that physicians' individualized judgments warrant greater
or most failures to treat may not fall within § 504, that discerning which failures to treat are discriminatory
may be difficult, and that applying § 504 in this area may intrude into the traditional functions of the State
do not support the categorical conclusion that the section may never be applied to medical decisions about
handicapped infants."); Univ. Hosp., State Univ. of N.Y at Stony Brook, 729 F.2d at 162 (Winter, J.,
dissenting) ("[A] decision not to correct a life threatening digestive problem because an infant has Down's
Syndrome is not a bona fide medical judgment.").
203 See Lesley, 250 F.3d at 55; see also Glanz v. Vernick, 756 F. Supp. 632, 638 (D. Mass. 1991) ("A
strict rule of deference would enable doctors to offer merely pretextual medical opinions to cover up
discriminatory decisions."); Glanz v. Vernick, 750 F. Supp. 39, 46 (D. Mass. 1990) (finding,
notwithstanding University Hospital, that plaintiff stated a claim for relief under the Rehabilitation Act by
alleging that his medical treatment was "denied because of unjustified consideration of... handicap").
204 Wendy F. Hensel & Leslie E. Wolf, Playing God: The Legality of Plans Denying Scarce Resources
to People with Disabilities in Public Health Emergencies, 63 FLA. L. REv. 719, 747 (2011) ("The cases
declining to review medical treatment decisions generally require scrutiny of professional judgment
rendered to a specific individual without predetermined limitations as to what care may be provided.
Because the professional's decision pertains to and can be evaluated in the context of a particular patient and
his actual need for treatment, it is necessarily based, at least to some extent, on an individualized
determination as mandated by the ADA. It may be that once this threshold is crossed, the legitimacy and
reasonableness of medical decisions are most appropriately evaluated in the context of state tort law and
professional standards of care, rather than in the context of antidiscrimination laws. In contrast, sweeping
policies that preclude or significantly limit entire categories of people with disabilities from receiving
medical care in advance of actual need necessarily are based on generalizations concerning status. Their
legitimacy depends on whether scientific evidence establishes that no individual in the excluded class could
possibly qualify for or benefit from the medical treatment at issue, or whether the exclusionary criteria is
actually based on prejudicial stereotypes and myths. It is precisely this type of inquiry that Congress
intended to reach through the ADA and the Rehabilitation Act, and such policies should be subject to
judicial review." (footnotes omitted)).
205 Id.
206 Id. at 748; see also Mary Crossley, Becoming Visible: The ADA's Impact on Health Care for
Persons with Disabilities, 52 ALA. L. REV. 51, 65 (2000) (describing "the case of Sandra Jensen, a woman
with Down syndrome who developed a need for a heart and lung transplant").
207 Danielle Richards, Note, The Defibrillation of NOTA: How Establishing Federal Regulation of
Waitltst Eligibility May Save Organ Transplant Patients with Disabilities from Flat-Lining, 87 S. CAL. L.
REV. 151, 187 (2013) (endorsing the "importance of individual evaluation of transplant candidates to
determine their postoperative compliance abilities"); Angela T. Whitehead, Note, Rejecting Organs: The
Organ Allocation Process and the Americans with Disabilities Act, 24 AM. J.L. & MED. 481, 495 (1998)
(arguing that UNOS should "consider a patient's candidacy based on his or her own characteristics and
capabilities" rather than adopting categorical rules).
208 CAL. HEALTH & SAFETY CODE § 7151.35 (West 2007); N.J. STAT. ANN. § 26:6-86.2 (West 2007);
see also Richards, supra note 207, at 188-90 (discussing these statutes).
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deference than higher level priority-setting choices is particularly interesting because it
inverts the frequent suggestion that priority-setting decisions that may disadvantage
specific patients or groups of patients should be made at the insurer or governmental
level, rather than by individual physicians, in order to safeguard the physician-patient
relationship and protect physicians from experiencing divided loyalties.2 9 However,
the Supreme Court has suggested that courts applying antidiscrimination law should
defer not only to physicians' medical judgments (which, as Hensel and Wolf suggest,
frequently reflect an individualized assessment of patients' needs210), but also to "the
judgments of public health officials in determining whether an individual is otherwise
,211qualified unless those judgments are medically unsupportable." Public health, unlike
clinical medicine, has as its emblem precisely the sort of broad-spectrum, societal,
non-individualized interventions (from water fluoridation to iodized salt to bans on
secondhand smoke) that may have differential impacts on individuals with different
212needs, and which Hensel and Wolf criticize.
There is not yet sufficient case law to provide a sense of how courts will view the
ACA's antidiscrimination provisions, and in particular whether they will interpret
these provisions to mandate the provision of insurance coverage or medical care to
individuals with specific illnesses, as courts have been reluctant to do where the ADA
213and the Rehabilitation Act are concerned . Some, however, have already called for
such an interpretation. A group of researchers at the Georgetown University Health
Policy Institute recently argued:
Prior to the ACA, federal and state law included some nondiscrimination
protections, but most have had only a limited effect in ensuring that
coverage meets the needs of all consumers. Through its broad
incorporation of new standards, the ACA is designed to address this gap
by prohibiting discrimination based on health status, disability, age, race,
gender, and sexual orientation, among other factors. In preventing
discrimination against certain groups-and, in particular, the sick-the
ACA takes significant steps towards ensuring that private health
insurance meets the needs of the most vulnerable. 4
They go on to state that "[b]y prohibiting insurers from offering coverage that
discriminates based on race, national origin, sex, age, disability, gender identity, sexual
orientation, expected length of life, or significant health needs, the ACA represents a
significant shift away from many existing discriminatory practices.",215 Although I
agree with these authors that existing antidiscrimination law has not substantially
ensured that coverage meets every customer's needs, I am less certain either
descriptively that the ACA ensures this outcome or normatively that such an outcome
209 See Hall, supra note 12, at 703-11 (reviewing opposition to priority setting at the physician level).
210 See Hensel & Wolf, supra note 204, at 744-50.
211 Sch. Bd. of Nassau Cnty., Fla. v. Arline, 480 U.S. 273, 286 n.15 (1987); cf Robert J. Moossy, Jr.,
Comment, Health Care Prioritization and the ADA: The Oregon Plan 1991-1993, 31 HOUS. L. REV. 265,
316-17 (1994) ("Within the scope of an entitlement program such as Medicaid, however, the decision of
what benefits to provide rests with public health officials so long as they are truly exercising their
professional judgment in a reasonable manner. It is part of a public health care professional's job to assess
treatment options and then decide, using their medically based health care judgment, whether that treatment
warrants implementation." (footnotes omitted)).
212 See Hensel & Wolf, supra note 204, at 724-28.
213 E.g., Alexander v. Choate, 469 U.S. 287, 303-04 (1985); Doe v. Mut. of Omaha Ins. Co., 179 F.3d
557, 563-64 (7th Cir. 1999); Modderno v. King, 871 F. Supp. 40, 42-43 (D.D.C. 1994).
214 KEITH ET AL., supra note 174, at 4.
215 Id. at9.
156 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 41 NO. 12015
would be desirable.
Others, conversely, have argued that the ACA's incorporation of the
Rehabilitation Act and other antidiscrimination law into its text already serves to bar
insurance designs that disadvantage patients and subgroups. An HIV advocacy group,
for instance, recently argued:
If single pill regimen antiretroviral therapy is excluded from a formulary,
for example, the necessity of reverting to a multi-pill regimen may result
in an increase in side effects and a lowered rate of compliance. This, in
effect, is a prohibited discrimination based on a disability-in this case,
HIV-that falls under the purview of the exchange regulator to address.
This sort of activity is prohibited under rules against benefit design
discrimination and under Section 1557.216
At least with respect to section 1557, which incorporates the Rehabilitation Act and
other antidiscrimination law, this suggestion is incorrect. Doe v. Mutual of Omaha
clearly states that the Rehabilitation Act does not prohibit insurance designs that in
practice disadvantage patients with HIV.217 The question is whether the ACA's new
provisions concerning health status discrimination legislatively override Doe as
applied to health insurers.
Waiting periods represent one area where specific guidance has already been
issued. Commenters on an Oregon statute complained that a twenty-four-month
waiting period for organ transplants violates the ACA's anti-discrimination
provisions. 2  During May 2014, Centers for Medicare and Medicaid Services (CMS)
issued guidance expressing concern that "waiting periods for specific benefits
discourage enrollment of or discriminate against individuals with significant health
needs or present or predicted disability," and stating that "a plan that includes a
waiting period for any type of transplant would discriminate against those whose
conditions make it likely that they would need a transplant: those with kidney disease,
heart conditions, or similarly critical and life-threatening ailments.",219 CMS went on to
state that "with respect to plans that must provide coverage of the essential health
benefit package, issuers may not impose benefit-specific waiting periods, except in
covering pediatric orthodontia, in which case any waiting periods must be reasonable
,220pursuant to section 156.125." CMS did also provide that "[tlhis clarification refers
to a waiting period that is applied uniformly to a specific benefit within the plan design
and not reasonable medical management,",221 thus leaving open whether waiting
periods that are part of evidence-based guidelines or medical custom would beacceptable under section 156.125.
216 Joshua L. Holmes, Human Rights and Health Care Exchanges: Affordable Care Act's
Antidiscrimination Provisions, HIV CLINICIAN, Winter 2014, at 1, 2, available at
http://www.deltaaetc.org/hcarticles/articles / 20as / 20pdf/winter/ 2020140/%20articles / 20as0/%2Opdf/ACA /
20antidiscriminationo2oprovisions.pdf.
21" Mut. of Omaha Ins. Co., 179 F.3d at 560, cert. denied,
528 U.S. 1106 (2000).
218 Letter from Alan Langnas, President, Am. Soc'y of Transplant Surgeons, and Daniel R. Salomon,
President, Am. Soc'y of Transplantation, to Laura Cali, Ins. Comm'r, Or. Dept. of Consumer Bus. Servs.
(Dec. 6, 2013) (on file with author), available at http://asts.org/docs/default-source/regulatory/asts-and-ast-
comments-to-oregon-insurance-division-december-9-2013.pdf.
219 CTR. FOR CONSUMER INFO. & INS. OVERSIGHT, CTRS. FOR MEDICARE & MEDICAID SERVS.,
FREQUENTLY ASKED QUESTIONS ON HEALTH INSURANCE MARKET REFORMS AND MARKETPLACE
STANDARDS 1 (2014), available at http://www.cms.gov/CCIIO/Re source s/Fact-Sheets-and-
FAQs/downloads/Final-Master-FAQs-5-16-14.pdf.
220 Id. at2.
221 id.
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CMS's opinion represents a major departure from pre-ACA court decisions
regarding insurance coverage, which were reluctant to strike down coverage decisions
that were uniformly applied, even when they worked to the disadvantage of some
patients . Courts have hitherto been highly deferential to the judgments of physicians
and hospitals when considering what constitutes appropriate treatment of a medically
defined class-what medicine gives, medicine can take away. 223 CMS's opinion
suggests that HHS, at least, is willing to intervene more aggressively in priority-setting
decisions to ensure that medically defined classes are not disadvantaged. This stance
has been welcomed by disease advocacy groups charging that "individuals with high-
cost chronic and acute conditions like cancer" are those at the greatest risk of
discrimination. 24 However, CMS leaves the justification for its position ambiguous
when it notes that waiting periods "discourage enrollment of or discriminate against"
patients with specific illnesses. The "discourage enrollment" language suggests
concern that private insurers will cherry-pick cheaper, healthier customers by failing to
provide benefits, such as transplants, sought by sicker, more costly patients. In such a
scenario, the cherry-picking insurers would be displacing the cost of treating sicker
patients onto their competitors in the market or onto government-provided plans of last
225resort. Such conduct would be inconsistent with the ACA's goal of expanding
226access to healthcare. However, the "discourage enrollment" language would not
justify prohibiting waiting periods within Medicaid plans such as Oregon's. Such
waiting periods do not deter the enrollment of patients needing transplants, since they
have no alternative to Medicaid. Rather, they impose a burden on patients needing
transplants in order to control costs and provide benefits to other plan participants.
Such a priority-setting decision involves a value judgment, but not obviously an
inappropriate one, particularly when refusing to impose a waiting period would
disadvantage other-perhaps less visible-Medicaid beneficiaries, such as children
needing preventive care. CMS would be making a mistake if it employed the
"discriminate against" language to classify waiting periods within Medicaid or
Medicare as impermissible discrimination.
CMS is also attempting to assess whether plans are employing discriminatory
benefit designs by conducting an "outlier analysis": Arkansas's regulations note that
"[w]ith respect to prescription drugs, CMS has indicated they intend to review plans
that are outliers based on an unusually large number of drugs subject to prior
1227authorization and/or step therapy requirements in a particular category and class."
222 See Orentlicher, supra note 118, at 78-81 (discussing Alexander v. Choate and its implications).
223 Margaret Gilhooley, Broken Back: A Patient's Reflections on the Process of Medical Necessity
Determinations, 40 VILL. L. REv. 153, 161-62 (1995).
224 Public Comment Letter from the Patients Equal Access Coal., to Kathleen Sebelius, Sec'y, Dep't of
Health & Human Servs. (Dec. 21, 2012) (on file with the National Brain Tumor Society), available at
http://www.braintumor.org/assets/docs/advocate-for-change/alerts-polls-
updates/2012 finalpeac speac comment letter on ehbproposed rule 11 11 13.pdf.
22 However, the ACA's provision for "risk corridors" that pay insurers bonuses for covering high-risk
patients attempts to prevent this outcome. See KAISER FAMILY FOUND., EXPLAINING HEALTH CARE
REFORM: RISK ADJUSTMENT, REINSURANCE, AND RISK CORRIDORS 8-9 (2014), available at
http://kff.org/health-reform/issue-brief/explaining-health-care-reform-risk-adjustment-reinsurance-and-risk-
corridors/.
226 Cf Letter from James H. Scully, Jr., Med. Dir. & CEO, Am. Psychiatric Ass'n, to Ctr. for
Consumer Info. & Ins. Oversight (Mar. 15, 2013) (on file with author), available at
http ://www.psychiatry.org/File /o20Library/Advocacy /20and /o20Newsroom/APA /o20on /20the /o201ssues
/Regulatory/3-15-13-Final-Letter-to-Issuers-on-Federally-facilitated-and-State-Partnership-Exchanges.pdf
("The primary goal of health reform is to provide health care access to a greater number of Americans. The
ACA's nondiscrimination provisions remain central to being able to achieve this goal.").
22 Memorandum from the Arkansas Insurance Department to All Licensed Insurers et al. 15 (Apr. 11,
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The outlier analysis approach is better grounded than blanket bans on priority-setting
efforts such as waiting periods, because it limits cherry-picking without impinging on
cost control. If a plan is subjecting an unusual number of drugs for a given condition to
prior authorization or step therapy, in comparison to other plans, this at least suggests
that the plan is attempting to discourage the enrollment of unhealthy individuals. 22
But if all plans are subjecting drugs for a certain condition to prior authorization, while
this may be disadvantageous for the condition's sufferers, it does not saddle any one
plan disproportionately with the costs of treating a costly condition and thus concern is
lessened that a single plan is cherry-picking customers.
CMS has also suggested additional ways in which it plans to prevent the use of
discriminatory benefit designs. CMS's 2014 Letter notes that "CMS also intends to
propose in future rulemaking a review of prescription drugs based on clinical
appropriateness that states may choose to implement.",229 CMS also notes that it will
scrutinize plans for "[d]iscriminatory cost-sharing language," which "would typically
involve reduction in the generosity of a benefit in some manner for subsets of
individuals other than based on clinically indicated common medical management
practices."'23° Like the restriction on waiting periods, this provision is ambiguous in its
justification, although its placement within a section that begins with a discussion of
practices that discourage the enrollment of ill patients may suggest that this scrutiny
would also focus on chery-picking rather than on disadvantage to specific subsets.
c. Discrimination Against Protected Classes
Other priority-setting decisions may target classes that are not defined in terms of
a medical condition. Some worry about discrimination against children, whose medical
231care is frequently low cost but has delayed benefits. Similarly, the National Health
Law Program has argued that "in the context of contraceptive care, medical
management techniques that limit, delay or deny coverage of a woman's chosen FDA-
approved method are never permissible," and that HHS should issue additional
2014) (on file with author), available at http://www.insurance.arkansas.gov/Legal/Bulletins/9-2014.pdf; see
also Memorandum from Todd E. Kiser, Comm'r, Utah Insurance Dep't, to Insurance Carriers Offering
Health Benefit Plans or Stand-Alone Dental Plans 8 (Mar. 4, 2014), available at
https:Hinsurance.utah.gov/legal-resources/bulletins/documents/2014-3 -Signed.pdf (similar).
228 CMS's 2014 Letter to Issuers in the Federally-Facilitated Marketplaces affirms that the purpose of
outlier analysis is to prevent cherry-picking. Memorandum from Ctr. for Consumer Info. & Ins. Oversight,
Ctrs. for Medicare & Medicaid Servs. to Issuers in the Federally-Facilitated Marketplaces 28 (March 14,
2014) (on file with author), available at http://www.cms.gov/CCIIO/Resources/Regulations-and-
Guidance/Downloads/2015-final-issuer-letter-3-14-2014.pdf [hereinafter Final Memorandum] ("In addition
to complying with EHB non-discrimination standards, [Qualified Health Plans (QHPs)] must not employ
market practices or benefit designs that will have the effect of discouraging the enrollment of individuals
with significant health needs. To ensure non-discrimination in QHP benefit design, CMS will perform an
outlier analysis on QHP cost sharing (e.g., co-payments and co-insurance) as part of the QHP certification
application process. QHPs identified as outliers may be given the opportunity to modify cost sharing for
certain benefits if CMS determines that the cost sharing structure of the plan that was submitted for
certification could have the effect of discouraging the enrollment of individuals with significant health
needs." (citations omitted)).
229 Draft Memorandum from Ctr. for Consumer Info. & Ins. Oversight, Ctrs. for Medicare & Medicaid
Servs. to Issuers in the Federally-Facilitated Marketplaces 30 (Feb. 4, 2014) (on file with author), available
at http://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/draft-issuer-letter-2 -4-
2014.pdf.
230 Final Memorandum, supra note 228, at 29.
231 Patience White, Testimony on Behalf of the American Academy of Pediatrics Before the U.S.
Department of Health and Human Services (Oct. 18, 2011), available at http://www.aap.org/en-
us/advocacy-and-policy/federal-advocacy/Documents/Patience White Testimony 10-18-1l.pdf.
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guidance to this effect. 32 The National Women's Law Center has suggested that,'while the [essential health benefits] rule states these requirements do not prevent
issuers from 'appropriately utilizing reasonable medical management techniques,'
these techniques cannot be used in ways that discriminate." 33 However, the language
of the regulation suggests that if a technique is reasonable, then it by definition does
not discriminate, even if it may disadvantage some patients.
In response to the regulations' lack of clarity about whether they permit priority-
setting decisions that work to the disadvantage of protected classes, the Family
Equality Council expressed concern about devolving all enforcement to states, and
called on CMS to "develop a clear standard for what constitutes a discriminatory
benefit design.",2 34 More specifically, the Council called for a broad definition of what
constitutes a discriminatory benefit:
This standard must address both individual cases of intentional
discrimination and benefit designs that are facially neutral but that have
the effect of systematically disadvantaging members of protected
classes. Ultimately, this standard must make clear that the determination
of whether a coverage limitation or exclusion is discriminatory should
turn on the degree to which the benefit design is based on sound
standards of clinical appropriateness rather than on arbitrary distinctions
between health conditions or personal characteristics. To assist federal
and state regulators and insurance carriers in rectifying discrimination in
benefit design, CMS should follow up on the final rule with
subregulatory guidance explaining how to evaluate products for
impermissible discrimination and providing examples of discriminatory
benefit designs such as those listed above. In addition, CMS should
require trained evaluators in each state to regularly and transparently
review insurance contracts for discriminatory benefit designs and to
ensure that issuers act quickly to remedy identified instances of
discrimination. Where CMS determines that a state is not fulfilling its
responsibilities in this area, CMS should establish a review procedure
that goes beyond existing procedures for Medicare Advantage and
Medicare Part D to focus on ensuring that all services deemed part of the
essential benefits are available to all eligible individuals for whom they
are medically necessary, without arbitrary discrimination on the basis of
any protected personal characteristic. 35
The Council's call for enforcement procedures that assess "clinical appropriateness"
and medical necessity recalls Rosenbaum's suggestion that HHS rely on clinical
236judgment when deciding when the consideration of a factor is discriminatory.
232 Erin Armstrong, Medical Management and Access to Contraception, NAT'L HEALTH L. PROGRAM
(May 1, 2013), http://www.healthlaw.org/publications/medical-management-and-access-to-contraception.
233 NATIONAL WOMEN'S LAW CENTER, AN OVERVIEW OF SECTION 1557, NONDISCRIMINATION
STANDARDS, AND THE AFFORDABLE CARE ACT: A TOOL FOR STAKEHOLDERS 7 (2013) (footnote omitted),
available at http://www.nwlc.org/resource/overview-section- 15 57-nondiscrimination-standards-and-
affordable -care -act-tool- stakeholders.
234 Public Comment Letter from Jennifer Chrisler, Exec. Dir., Family Equal. Council, to Ctrs. for
Medicare & Medicaid Servs., Dep't of Health & Human Servs. (Dec. 20, 2012) (on file with author),
available at http://www.familyequality.org/ asset/cst5jd/Family-Equality-Council-Comments-for-HHS-
EHB-Proposed-Rule-12 20.pdf. The Family Equality Council is a lesbian, gay, bisexual and transgender
advocacy group. Id.
235 Id.
236 INST. OF MEDICINE, supra note 13 9, at 87.
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However, its discussion of "benefit designs that are facially neutral but that have the
effect of systematically disadvantaging members of protected classes",237 draws
attention to a challenge that antidiscrimination statutes have systematically faced-
whether they only target intentional discrimination, or also reach what is called
"disparate impact." 238 The Supreme Court has been increasingly hesitant to find in
favor of plaintiffs alleging disparate impact under a variety of antidiscrimination
statutes. 39 It is unclear whether the ACA's antidiscrimination language will form anexception to this trend, or instead continue it.
D. ADDITIONAL REGULATIONS ON PLANS OFFERED THROUGH EXCHANGES
While the Essential Health Benefit provisions discussed above apply to plans
offered through Exchanges, the ACA also contains two sections that further regulate
plans offered through the Exchanges.
1. Preventing Death at Any Cost
First, the ACA prohibits Exchanges from excluding plans "on the basis that the
plan provides treatments necessary to prevent patients' deaths in circumstances the
Exchange determines are inappropriate or too costly."'24° This provision has limited
scope. At least on its face, it does not require that plans provide treatments necessary
to prevent patients' deaths, nor does it exempt plans from having to provide essential
241health benefits or meet the other requirements that Exchanges impose . If plans are
providing costly lifesaving treatments, then they are affording this either by reducing
their profits, raising premiums, or cutting benefits elsewhere. All these choices are
perfectly acceptable-at least in a competitive marketplace-as patients can take their
business elsewhere if they prefer lower premiums or more generous benefits at the
expense of heroic treatments for rare, costly diseases.
However, if this language were interpreted to allow plans to fail to provide
essential health benefits, or to exempt programs from the ACA's other regulations on
health plans, it could pose problems. Such a conflict could arise if providing costly
lifesaving treatments led to a provider receiving low scores on clinical quality
measures, if doing so interfered with the pursuit of quality improvement, or if a benefit
design that provided such treatments discouraged the enrollment of individuals with
serious health needs. The last might initially seem improbable, but such a scenario is
possible if, for instance, a plan prominently offered a costly lifesaving treatment for
rare childhood diseases, one that might be of little value to older patients with chronic
conditions that cost the insurer more to treat.242
Another effect of this provision is that it would limit Exchanges' efforts to apply
23 Chrisler, supra note 234.
238 Ricci v. DeStefano, 557 U.S. 557, 577 (2009) ("Title VII prohibits both intentional discrimination
(known as 'disparate treatment') as well as, in some cases, practices that are not intended to discriminate but
in fact have a disproportionately adverse effect on minorities (known as 'disparate impact').").
239 See Ian Haney-Lopez, Intentional Blindness, 87 N.Y.U. L. REV. 1779, 1781 n.3 (2012) (collecting
examples); see also Ricci, 557 U.S. at 594 (Scalia, J., concurring) ("Whether, or to what extent, are the
disparate-impact provisions of Title VII of the Civil Rights Act of 1964 consistent with the Constitution's
guarantee of equal protection?").240 42 U.S.C. § 1803 l(e)(1)(B)(iii) (2012).
241 Id.
242 Cf Lior Jacob Strahilevitz, Exclusionary Amenities in Residential Communities, 92 VA. L. REV. 437
(2006) (noting that costly amenities can serve to exclude disadvantaged individuals from community
membership).
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traditional cost-effectiveness analysis as a cutoff for which plans are included as
qualified health plans: even if preventing deaths via costly treatments reduces a plan's
243cost-effectiveness, Exchanges may not use that fact as a reason to exclude a plan.
However, Exchanges may still use effectiveness and cost-effectiveness data to provide
consumers with information. 244 For example, the same section of the ACA also
provides that the Secretary "shall develop a rating system that would rate qualified
health plans offered through an Exchange in each benefits level on the basis of the
relative quality and price," and "shall include the quality rating in the information
provided to individuals and employers.",245 These price-quality ratings could employ
traditional cost-effectiveness data, even if they led to plans that offer costly lifesaving
care receiving lower ratings, since the data is not being used to block access to plans,
but to inform consumers about the different options available within different plans.
Finally, the language employed here-that of "preventing death"-is notable.
Medical treatments can extend life, but they cannot, ultimately, prevent death. The
idea of a clear cutoff between treatments that prevent death and those that do not is
dubious. While a very few treatments may improve quality of life without increasing
its length, many others serve to extend the length of life. Placing special importance on
preventing imminent death serves to endorse what Albert Jonsen calls the "Rule of
Rescue," which places special importance on saving someone from imminent death,
regardless of the cost and, perhaps more importantly, regardless of whether that person
246will then be in stable health or will instead be menaced by other health problems.
While this principle is frequently embraced in practice, it has also been frequently
241criticized as an inappropriate and wasteful method of distributing scarce resources.
2. Clinical Trials and "Life-Threatening Conditions"
The second provision that prioritizes the prevention of imminent death refers to
2481clinical trials. It requires that health insurance plans not deny individuals
participation in certain clinical trials, nor discriminate against individuals who
participate in such trials, and that they receive coverage for routine costs associated
with trial participation. 49 However, the language requires only that patients be
allowed, without disadvantage, to participate in "a phase I, phase II, phase III, or phase
IV clinical trial that is conducted in relation to the prevention, detection, or treatment
of cancer or other life-threatening disease or condition." 250 It defines a life-threatening
condition as "any disease or condition from which the likelihood of death is probable
unless the course of the disease or condition is interrupted.",251
Yet there are many serious medical conditions that do not fall under this category,
243 42 U.S.C. § 1803 l(e)(I)(B)(iii) (2012).
244 42 U.S.C. § 1803 1(c)(3).
245 id.
246 Albert R. Jonsen, Bentham in a Box: Technology Assessment and Health Care Allocation, 14 L.
MED. & HEALTH CARE 172, 174 (1986).
241 See Persad et al., supra note 11, at 424-25; see also Leonard M. Fleck, Last Chance Therapies: Can
a Just and Caring Society Do Health Care Rationing When Life Itselfis at Stake?, 2 YALE J. HEALTH POL'Y
L. & ETHICS 255, 275 (2002) (noting that "[i]f all ... individuals could make themselves visible victims of
rationing in need of rescue, it would subvert all just schemes of health care rationing, including last chance
therapies.").
248 42 U.S.C. § 300gg-8.
249 42 U.S.C. § 300gg-8(a)(1)(A)-(C).
250 42 U.S.C. § 300gg-8(d)(I).
25 42 U.S.C. § 300gg-8(e).
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252including communicable diseases like human papilloma virus (HPV), neurological
conditions like autism, 253 and other conditions such as chronic pain.254 Indeed, some of
these conditions are arguably more serious and pressing healthcare priorities than some
life-threatening conditions. For instance, untreated heart arrhythmia will almost
certainly lead to imminent death, but we have a sound grasp on effective treatments,
255namely pacemakers. However, while autism does not "lead to death unless
interrupted," we have no idea how to effectively treat it, and it can impose serious
256burdens on individuals with autism and their families. Research on interventions for
autism is therefore almost certainly more important than research on alternative
treatments for heart arrhythmias. Yet the ACA's emphasis on preventing imminent
death seemingly permits healthcare plans to deny patients with non-life-threatening
conditions access to clinical trials that could benefit them and could also advance the
development of treatments for those conditions. By prioritizing life-threatening
conditions over communicable diseases or chronic and painful illnesses, this provision
imposes a top-down set of priorities that does not necessarily reflect scientific or
medical expertise, cost-effectiveness, clinical effectiveness, or the values of patient
communities. Indeed, on the expansive understanding of discrimination that CMS's
prohibition on waiting periods suggests, this prohibition might discriminate against
patients with serious conditions that are not life-threatening.
III. ACHIEVING COST CONTROL AND QUALITY IMPROVEMENT WITHIN
THE ACA'S LIMITS
While the ACA, as I have argued, likely goes too far in limiting the use of
traditional cost-effectiveness analysis, it also offers an opportunity for healthcare
funders and decision makers to think innovatively about how to control costs and
improve quality without falling afoul of the ACA's requirements. In this section, I
consider three aspects of the ACA: (1) its emphasis on fairness to people with
disabilities; (2) its discussion of age weighting; and (3) its antidiscrimination
provisions. Additionally, I propose ways that healthcare priority setting can change in
order to take these requirements into account.
A. DISABILITY
Rather than attempting to use traditional cost-effectiveness analysis in
combination with other factors and to avoid the "threshold" language, PCORI could
treat the restrictions as an opportunity to design a unit of measurement for cost-
effectiveness that does not disadvantage people with disabilities.
The challenge for those attempting to improve cost-effectiveness while not
disadvantaging people with disabilities is to achieve these three goals:
a) Prioritize treatments that improve length of life;
b) Prioritize treatments that cure disabling conditions, or prevent people
252 Human papillomavirus (HPV) and cervical cancer, WORLD HEALTH ORG.,
http://www.who.int/mediacentre/factsheets/fs380/en (last updated Nov. 2014).
253 Autism Fact Sheet, NAT'L INST. NEUROLOGICAL DISORDERS & STROKE, http://www.ninds.nih.gov/
disorders/autism/detail autism.htm (last updated Nov. 6, 2014) [hereinafter Autism Fact Sheet].
254 NINDS Chronic Pain Information Page, NAT'L INST. NEUROLOGICAL DISORDERS & STROKE,
http://www.ninds.nih.gov/disorders/chronicpain/chronicpain.htm (last updated Dec. 18, 2014).
255 See Frangois Roubille & Jean-Claude Tardif, New Therapeutic Targets in Cardiology Heart
Failure andArrhythmia: HCN Channels, 127 CIRCULATION 1986, 1993 (2013).
256 Autism Fact Sheet, supra note 53.
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from suffering disabilities; and
c)Regard extending the lives of people with disabilities and extending
the lives of people without disabilities as equally choiceworthy.
QALY-based methods achieve the first two goals, but not the third."' Switching
to a simple life year method achieves the first and last goal, but not the second.
As an alternative, I propose adopting a multidimensional measure of cost-
effectiveness, which treats life extension and quality improvement as independent but
relevant factors, rather than combining them into a single measure. Call this the LYAQ
(life years and quality) method. To illustrate, under the LYAQ method, extending the
length of someone's life by thirty years at a cost of $300,000 would have a cost-per-
life-year of $10,000. Improving the quality of someone's life by curing or preventing
blindness would also have a value, say $50,000. But, once blindness is cured or
prevented, the fact that the person whose life is extended is sighted rather than blind is
not used as a "weighting" factor in assessing the value of the intervention.
The LYAQ method does not treat an extra year of life for an older person as less
important, as an age-weighted view does, nor does it treat an extra year of life for a
disabled person as less important, as the QALY view does. Rather, it treats an extra
year of life as equally important for everyone, but gives priority to those who can
receive more future life from a given treatment: its aim is to get the greatest "bang for
the buck," to employ medical resources in a way that extends life as much as possible.
The reason for giving the older or more disabled person lower priority, on the forward-
looking view, is not that they have enjoyed more past life or that the future life they
gain will be of a lower quality; rather, it is that their age or disability prevents them
from gaining as much future life from the treatment. A younger or less disabled person
with a limited life expectancy would receive the same treatment, on the forward-
looking view, as someone whose limited life expectancy is caused by age or disability.
The LYAQ method has some counterintuitive features. In particular, this method
treats an intervention that cures blindness as equally important regardless of whether
treatment will allow a patient to enjoy full vision for a lifetime or only for a few years.
However, these features seem necessary to prevent disability discrimination.
Furthermore, there are empirical reasons to believe that the primary harm of disability
comes during the period of adaptation to disability, rather than through ongoing
disability. 5' The LYAQ approach captures this phenomenon. It also does a better job
of responding to the potential incommensurability of length and quality.
This method could be brought closer to traditional cost-effectiveness analysis,
while still minimizing the disadvantage to disabled individuals, by only counting
additional years of life as valuable if keeping a patient alive in that condition would
not constitute medical futility. This unit might be called a "non-futile life year"
(NFLY). Shifting from a QALY to a NFLY metric would capture one part of what is
valuable about considering quality, while avoiding discrimination against people with
disabilities such as blindness or mobility impairment. It would also base priority-
setting decisions on a concept-medical futility-that is accepted by legal decision
makers. 25 9 The NFLY proposal resembles the medical ethicist Frances Kamm's
2. For a recognition of this limitation, see Paul Menzel, How Should What Economists Call "Social
Values" Be Measured?, 3 J. ETHiCS 249, 260 (1999) (labeling this problem the "QALY trap").
28 See, e.g., John Bronsteen et al., Hedonic Adaptation and the Settlement of Civil Lawsuits, 108
COLUM. L. REV. 1516, 1529-30 (2008).
2 9 See TEx. HEALTH & SAFETY CODE ANN. § 166.046 (West 2010) (delineating procedures for
stopping futile treatments); Thaddeus Mason Pope, Dispute Resolution Mechanisms for Intractable Medical
Futility Disputes, 58 N.Y.L. SCH. L. REv. 347, 362 (2014). But see Meir Katz, When is Medical Care
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suggestion that what matters is not quality-adjusted life years, but what she calls
"adequate conscious life. 260
B. AGE-WEIGHTING
Despite the rhetoric about "death panels" and "killing Grandma" that
accompanied the ACA's introduction, surveys of the public systematically show an
endorsement of the view that, all else equal, younger individuals should receive some
261priority over older individuals when scarce interventions are at stake.
There is no existing law that categorically prevents providers from engaging in
age weighting when setting priorities, and the public preferences suggest that age
262weighting has broad popularity. Additionally, age weighting does not obviously
involve a self-serving bias: while not everyone will develop a particular disability or
263illness, almost everyone will live through different stages of life. This counsels in
favor of an interpretation of the ACA that permits medical providers to engage in age
weighting, particularly when the interventions at stake-as with organs for
transplantation-are absolutely scarce. 64
What has explained resistance to age weighting in priority-setting debates? One of
the clearest explanations involves a problem that the noted medical ethicist Norman
Daniels identified more than twenty years ago: losses for older patients due to age
265weighting are not always converted into gains for younger patients . Rather, age
weighting might be used to generate surpluses of money that are used in the private
sector to increase health insurers' profits or in the public sector to pursue other
priorities such as military spending. The possibility that healthcare losses for some will
not translate into greater access for others, but instead be siphoned off to projects
outside the healthcare system, explains why "saying no to patients in the United States
is so hard., 26 6
However, the ACA's provisions help to reduce the risk that age weighting will be
used to bolster military spending or increase health insurers' profits. Most
prominently, the ACA requires that health insurers return excess revenue to plan
subscribers rather than retaining it as profit. 67 This provision makes healthcare more
like the "closed system" that Daniels discusses, 268 and makes age weighting less
objectionable than it hitherto would have been, though not necessarilyunobjectionable.
"'Futile"? The Institutional Competence of the Medical Profession Regarding the Provision of Life-
Sustaining Medical Care, 90 NEB. L. REv. 1, 7 (2011).
260 KAMM, supra note 104, at 236.
261 See Paul Dolan et al., QALY Maximisation and People's Preferences: A Methodological Review of
the Literature, 14 HEALTH ECON. 197, 201-02 (2005); Olof Johansson-Stenman et al., Saving Lives Versus
Life-Years in Rural Bangladesh: An Ethical Preferences Approach, 20 HEALTH ECON. 723, 729 (2011).
262 Aki Tsuchiya et. al., Measuring People's Preferences Regarding Ageism in Health: Some
Methodological Issues and Some Fresh Evidence, 57 SOC. SC. & MED. 687, 688 (2003).
263 See DANIELS, supra note 102, at 85; cf Persad et al., supra note 11, at 425.
264 Contra Jessica Dunsay Silver, From Baby Doe to Grandpa Doe: The Impact of the Federal Age
Discrimination Act on the 'Hidden'Rationing of Medical Care, 37 CATH. U. L. REv. 993, 1066-67 (1988)
(rejecting the use of age in organ allocation).
26' Norman Daniels, Why Saying No to Patients in the United States Is So Hard: Cost Containment,
Justice, and Provider Autonomy, 314 NEW ENG. J. MED. 1380, 1380-81 (1986); see also Leonard M. Fleck,
Just Health Care Rationing: A Democratic Decisionmaking Approach, 140 U. PA. L. REV. 1597, 1626
(1992).
266 Daniels, supra note 265, at 1380.
267 42 U.S.C. § 300gg-18(b)(1) (2012).
268 Daniels, supra note 265, at 1381-83.
PRIORITY SETTING, COST-EFFECTIVENESS, AND THE ACA
C. FAIRNESS TO DIVERSE SEGMENTS OF THE POPULATION
The ACA presents healthcare policymakers with an opportunity to consider, in
greater depth, the equity of how benefits are distributed. QALY-based approaches
have traditionally looked at the total health impact on the population when calculating
cost-per-QALY figures, rather than considering who receives the health benefits from
specific interventions.269 As the health economist John Mullahy notes, this means that
QALY approaches are insensitive to different interventions' effects on health
inequalities between individuals or groups, so long as the total number of QALYs
270under each policy is the same.
I have argued above that priority-setting approaches that favor individuals whose
diseases happen to be cost-effectively treatable are not unfair.271 Disease status is not
an inappropriate basis for medical judgments, nor are individuals with specific
diseases considered members of protected classes for legal purposes. In contrast,
priority setting should aim to be fair to individuals from diverse groups within a
population: if prostate cancer and colon cancer treatments are equally good from a
cost-per-QALY perspective, but prostate cancer treatments provide health benefits
only to men, the ensuing disparity in benefits between the sexes seems relevant. The
same is true for treatments that have disparate benefits for particular racial or ethnic
groups.
Ultimately, rather than solely focusing on total population health, a more complete
priority-setting metric would consider health inequalities as well. The adoption of a
more complete measure would parallel, for example, the decision to deemphasize
antigen matching criteria for kidney transplantation, which helped to drastically reduce
272the extent that black patients are disadvantaged when seeking organ transplants.
V. CONCLUSION
Thinking seriously about priority-setting challenges within the ACA's reimagined
vision of American healthcare suggests the possibility of a more pluralistic vision of
healthcare, where some choose plans that prevent imminent death at any cost while
others choose plans that spend more heavily on cost-effective care. By retaining a
private insurance system rather than transitioning to a single-payer system like the
British National Health Service, the healthcare reform efforts that culminated in the
ACA left open the possibility that different health plans could cater to the
heterogeneous preferences of different members of the public. 273
Ultimately, my verdict on the ACA's effect on priority setting is mixed. The
provisions I discussed have the potential to be deeply consequential: they cannot be
easily circumvented by advocates of traditional, technocratic cost-effectiveness
269 John Mullahy, Live Long, Live Well: Quantifying the Health of Heterogeneous Populations, 10
HEALTH ECON. 429, 430 (2001).
201 Id. at 435.
271 See supra Part II.C.3.
22 Coleman, supra note 10, at 1122 ("For example, the system does not rely on HLA antigen matching
for kidney transplantation, in part because such an approach would systematically favor white over black
organ recipients."); see also Erin C. Hall et al., Effect of Eliminating Priority Points for HL4-B Matching on
Racial Disparities in Kidney Transplant Rates, 58 AM. J. KIDNEY DISEASES 813, 813 (2011); cf Ian Ayres
et al., Unequal RacialAccess to Kidney Transplantation, 46 VAND. L. REV. 805, 843-50 (1993) (suggesting
how kidney allocation protocols might be revised to remedy racial disparities in allocation).
273 Cf EZEKIEL J. EMANUEL, THE ENDS OF HUMAN LIFE: MEDICAL ETHICS IN A LIBERAL POLITY 178-
244 (1991) (proposing a healthcare system that includes a variety of "community health programs" catering
to individuals with different values).
166 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 41 NO. 12015
analysis, as some have asserted. As such, they are potentially dangerous: to the extent
that they promote a view that considerations of cost and effectiveness are completely
outweighed by the gain of even a moment of life, they threaten the possibility of
achieving the healthcare system we need-one that supports public health while
reining in rising costs. But they also offer the possibility of breaking through a standoff
between technocrats and social conservatives, with the former clinging to
oversimplified measures like the QALY while the latter criticize any consideration of
cost when lives are at stake. Taking seriously the challenge that the ACA's provisions
pose requires a health care system that does justice to the complexity of our values.
